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1 Introduction 
1.1 G protein coupled receptors 
G protein coupled receptors (GPCRs) are signaling proteins which are found on the cell 
surface and transduce signals from outside the cell to the inside of a cell, thus allowing 
communication between cells, tissues and organs by responding to a wide range of 
modulators, such as hormones, neurotransmitters, lipids, peptides, nucleotides, ions and 
photons (Gether and Kobilka, 1998; Lagerström et al., 2008). With about 800 receptors, 
GPCRs represent the largest gene family in the mammalian genome, and, as widely 
expressed in the human body, GPCRs are involved in a vast range of physiologic and 
pathologic processes relying on cell signaling (Lundstrom, 2006). Related to their 
involvement in diseases like hypertension, pain, asthma, allergy and cancer, GPCRs are 
important pharmacological targets in drug development (Jacoby et al., 2006; Lappano 
and Maggiolini, 2011). About one third of currently used drugs are targeted against 
GPCRs, acting on approximately thirty receptors (Overington, 2006).  
GPCRs consist of a single polypeptide chain spanning through the cell membrane seven 
times with three intracellular loops (ICLs) and three extracellular loops (ECLs), 
resulting in an extracellular N terminus and an intracellular C terminus. Structural 
comparison amongst GPCRs prove that the transmembrane (TM) helices contain highly 
conserved amino acid features, whereas the extra- and intracellular regions vary, which 
is due to the divergent ligands and signaling molecules interacting with GPCRs. Within 
the highly conserved TM helices, a highly conserved DRY motif at the C-terminal end 
of TM III and a highly conserved NPXXY motif in TM VII are most prominent and 
have been determined to stabilize the inactive receptor conformation. Important regions 
for receptor-G protein interaction are the intracellular loops 2 and 3, and intracellular 
loop 3 also contains recognition sites for protein kinases, presented by serine and 
threonine residues (Burstein et al., 1995; Krupnick and Benovic, 1998). 
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Figure 1: Scheme of a G protein coupled receptor. 
 
GPCRs can be divided into five major subfamilies: the Rhodopsin-like receptors, the 
Secretin receptors, the Adhesion receptors, the Glutamate receptor family and the 
Frizzled/Taste2 receptors.  
1.2 G proteins  
Heterotrimeric G proteins are membrane-associated polypeptides serving as most 
common signal transducers of GPCRs. They consist of the subunits Gα, Gβ and Gγ, and 
in humans, there are fifteen genes encoding for Gα, five for Gβ and eleven for Gγ 
(Hurowitz et al., 2000). In the inactive state, the three subunits form a heterotrimer with 
a GDP bound to the Gα subunit (Gα-GDP). Upon G protein activation, GDP is released 
and exchanged for GTP, and subsequently Gα-GTP either dissociates from Gβγ or, 
alternatively, Gαβγ undergoes intramolecular rearrangement (Rosenzweig et al., 2007; 
Digby et al., 2006). Subsequently, Gα as well as Gβγ interact with cellular effectors 
close to the cell membrane, hereby inducing production of second messengers, which in 
turn activate further cellular pathways. G proteins are classified into four subfamilies 
due to structural determinants of the Gα subunit: Gαs, Gαi/o, Gαq/11 and Gα12/13 (Simon 
et al, 1991, Milligan and Kostenis, 2006). 
Gαs was the first G protein to be discovered (Northup, et al., 1980, Ross, E. M. and 
Gilman, 1980) and is the stimulatory protein for adenylyl cyclase, leading to an increase 
of intracellular levels of the second messenger cAMP. The Gαs subfamily is comprised 
of Gαolf and the Gαs gene splice variants Gαs(L) and Gαs(XL) (Milligan and Kostenis, 
1 Introduction 
 
3 
2006). Gαs proteins are ubiquitously expressed, whereas Gαolf is mainly found in 
olfactory neurons and in certain CNS ganglia (Milligan and Kostenis, 2006). 
 
Gα proteins belonging to the subfamily of Gαi/o proteins inhibit activity of adenylyl 
cyclase (Bokoch, et al., 1984, Sternweis and Robishaw, 1984), which results in a 
decrease of cellular amounts of cAMP. The Gαi/o subfamily comprises the subunits 
Gαi1, Gαi2, Gαi3, and Gαo, which are abundantly expressed. 
Gα proteins from the Gαq/11 subfamily activate β-isoforms of phospholipase C, which 
induces production of inositol phosphate and diacylglycerol, which in turn triggers 
cellular events resulting in calcium flux from intracellular stores. Thus, inositol 
phosphate and calcium are the second messengers produced upon activation of Gα 
proteins belonging to the Gαq/11 subfamily (Cockcroft and Gomperts, 1985; Milligan 
and Kostenis, 2006). The Gαq/11 G protein subfamily comprises Gαq, Gα11, Gα14, Gα15, 
Gα16, where Gαq and Gα11 are almost ubiquitously expressed in contrast to Gα14, Gα15, 
Gα16 which are more restrictedly expressed in hematopoietic cells (Wilkie et al., 1991).     
 
Activation of Gα12 and Gα13 proteins does not result in second messenger formation, but 
in increasing activity of the downstream effector small GTPase RhoA, which is 
mediated by a subgroup of guanine nucleotide exchange factors for Rho. Gα12 and the 
Gα13 proteins are expressed ubiquitously (Kurose, 2003, Kelly et al., 2007; Worzfeld et 
al., 2008). 
1.3 GPCR signaling 
GPCR signaling is initiated upon agonist binding to the receptor, causing a 
conformational change of receptor structure, which enables the receptor to interact with 
intracellular effectors. These intracellular effectors in turn induce cellular signaling 
cascades and hereby transfer the agonist-induced receptor stimulation into a cell 
response. GPCR signaling can mechanistically be divided into G protein-dependent and 
G protein-independent signaling. 
At G protein dependent signaling, heterotrimeric G proteins located at the cell 
membrane are activated by agonist-stimulated GPCRs, causing a conformational change 
in the G protein heterotrimer, which leads to release of GDP from the nucleotide 
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binding pocket of Gα. Receptor-mediated G protein activation is thought to be initiated 
through contact between the activated GPCR and the Gβγ subunit of the G protein 
heterotrimer (Bourne, 1996; McIntire, 2009). After GDP release from Gα, subsequently 
a GTP binds to Gα. The Gα-GTP as well as the Gβγ subunit can interact with cellular 
effectors and during these processes, the Gα-GTP can either remain bound to Gβγ or 
dissociate from the Gβγ dimer, as evidence exists for the occurrence of both states 
(Janetopoulos et a., 2001; Bünemann et a., 2003). Cellular effectors and processes 
activated by G protein-dependent signaling are K+ channels, Src tyrosine kinases and 
the tubulin GTPase (Gαs and Gαi/o), protein kinase A, the exchange protein directly 
activated by cAMP and the transcription factor cAMP response element binding protein 
(Gαs), protein kinase C and guanine nucleotide exchange factors (Gαq/11), 
phospholipase C (Gαq/11 and Gβγ), phosphoinositol kinase 3 (Gβγ) as well as Rho 
kinases and serum response transcription factor (Gα12/13) (Siehler, 2009; Milligan and 
Kostenis, 2006; Oldham and Hamm, 2009; Woehler and Ponimaskin, 2009). 
G protein-dependent signaling of GPCRs is terminated by G protein coupled receptor 
kinases (GRKs), which phosphorylate the receptor and enable binding of Arrestins to 
the receptor that in turn sterically interdicts further receptor-G protein contact.  
Despite its function to terminate G protein-dependent GPCR signaling, Arrestins also 
play a role for G protein-independent GPCR signaling by acting as scaffold proteins, 
linking the GPCR to intracellular effectors such as the mitogen-activated protein kinases 
(MAPK) including extracellular-regulated kinase 1/2 (ERK 1/2), the c-Jun N-terminal 
kinase 3 (JNK3) and p38 (DeFea et al., 2000). Other GPCR signaling processes and 
effectors reported to be activated G protein independently involve GRKs, PDZ domain 
containing proteins, janus protein kinase/signal transducers and activators of 
transcription (JAK/STAT), or Src-protein tyrosine kinases (Woehler and Ponimaskin, 
2009; Sun et al., 2007; Millar and Newton, 2010). 
1.4 5-oxo-eicosatetraenioc acid 
The fatty acid 5-oxo-eicosatetraenoic acid (5-oxo-ETE, OXE) belongs to the group of 
eicosanoids, which comprises oxygenated metabolites of arachidonic acid (AA) 
featuring a twenty carbon chain structure. OXE is a metabolite of the 5-lipoxygenase (5-
LO) pathway of AA (fig. 2), which is abundantly present in cell membrane 
phospholipids. At the 5-LO pathway of AA, the fatty acid is converted into 5-
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hydroperoxy-eicosatetraenoic acid (5-HpETE) via oxidation (Funk, 2001). 5-HpETE is 
further transformed by 5-LO into the leukotriene precursor leukotriene A4 (LA4) or is 
reduced to 5-hydroxy-eisosatetraenoic acid (5-HETE) by peroxidases, which is then 
further converted into OXE. 
 
 
Figure 2: Formation of 5-oxo-ETE and other 5-lipoxygenase products from arachidonic 
acid. Taken from OXE and the OXE receptor, Grant et al. (2009). 
Conversion of 5-HETE into OXE is implemented by 5-hydroxyeicosanoid 
dehydrogenase (5 HEDH), which is highly selective for 5S-HETE and needs NADP+ as 
cofactor at high intracellular levels (Powell et al., 1992; Erlemann, 2007). Naturally, 
NADP+ is found at low intracellular levels due to its preferred complement NADPH. In 
neutrophils, increasing intracellular levels of NADP+ were determined to be produced 
by respiratory burst and oxidative stress due to activation of NADPH oxidase-2 
(NOX2), converting NADPH into NADP+ by oxidation (Powell et al., 1994), thus 
inducing increased OXE formation. OXE production has been reported for monocytes 
(Zhang et al., 1996), dendritic cells (Zimpfer et al., 2000), platelets (Powell et al., 1999), 
endothelial (Erlemann et al., 2006), epithelial (Erlemann et al., 2007) and airway 
smooth muscle cells (Erlemann et al., 2007; Grant et al., 2009). OXE induces calcium 
mobilization, actin polymerization, CD11b expression and L selectin shedding, and as it 
is determined to be a potent chemoattractant for eosinophils and neutrophils (Powell et 
al., 2005), OXE is suggested to play a pivotal role in inflammatory diseases (Zimpfer et 
al., 1998; Jones, 2006; Grant et al., 2009).   
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1.5 5-oxo-ETE receptor 
5-oxo-ETE was recently identified as endogenous ligand for a Gi coupled GPCR. The 
receptor gene was independently cloned by three groups (Hosoi et al., 2002; Jones et al., 
2003; Takeda et al., 2002). Due to the agonist 5-oxo-ETE (OXE), the receptor was 
named OXE-receptor (OXE-R) by the International Union of Pharmacology (Brink et 
al., 2004). There are differences between the OXE-R sequence cloned by the groups of 
Hosoi and Takeda (also referred to as TG1019), and the OXE-R sequence cloned by 
Jones et al. (referred to as R527): The N terminus of TG1019 is 39 amino acids longer 
than that of R527 and possesses leucine at position 368 instead of valine. However, 
these differences do not alter the biological activity of the receptor, indicating that the N 
terminus of the OXE-R plays a minor role in signaling (Brink et al., 2004). 
Phylogenetically, the OXE-R is closest related to the hydroxy-carboxylic acid receptors 
GPR109A (also referred to as HM74A) and the GPR81 (Ahmed et al., 2009), with 40 % 
sequence identity at the amino acid level (Jones et al., 2005). The OXE-R was 
determined not to respond to a variety of prostaglandins, leukotrienes and lipoxins 
(Hosoi et al., 2003), respectively, but agonistic activity on the OXE-R was determined 
for the mead acid metabolites 5-hydroxy-6,8,11-eicosatrienoic acid, 5-oxo-20:3 and two 
6-trans isomers of leukotriene B(3) (Patel et al., 2008) as well as for bioactive peptides 
discovered by Sasaki et al. (2008).  
Expression of the OXE-R was determined in peripheral leukocytes, lung, kidney, liver, 
spleen and a variety of tumor cells (Jones et al., 2003; Sundaram and Ghosh, 1998; 
O´Flaherty et al., 2005). The OXE-R was suggested to couple to Gαi/o proteins, since it 
had been shown that OXE induced calcium increase in neutrophils and inhibited 
forskolin-stimulated adenylyl cyclase-dependent cAMP production in CHO and 
HEK293 cells transfected with the OXE receptor (Hosoi et al, 2002, Jones et al., 2003). 
OXE-R coupling to Gαi/o proteins was confirmed by the use of PTX (Powell et al., 
1996; Norgauer et a., 1996; O´Flaherty et al., 1996), a toxin which inactivates Gαi/o 
proteins by irreversible ADP-ribosylation (Kaslow, et al., 1987). Since OXE-mediated 
calcium mobilization and chemotaxis of transfected CHO cells were inhibited by PTX 
and by the phospholipase C inhibitor U73122, it was suggested that these responses 
were mediated by Gβγ signaling of Gαi/o proteins (Hosoi et al., 2005). It was also shown 
that OXE activates phosphoinositide-3 kinase (PI3K), which was suggested to be 
involved in chemotaxis of transfected CHO cells since the PI3K inhibitor LY294002 
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was able to block this reaction (Hosoi et al., 2005). Further cellular events induced by 
OXE-R signaling are phosphorylation of ERK 1/2 as shown for neutrophils (O´Flaherty, 
1996), eosinophils (Langlois et al, 2009; O´Flaherty et al., 1996), PC3 cells (O´Flaherty 
et al., 2002) and OXE-R transfected CHO cells (Hosoi et al., 2005), as well as protein 
kinase C-delta (PKC-delta) and PKC-zeta signaling (Langlois et al., 2009). Since OXE 
is produced by inflammatory cells and elicits immune cell infiltration to inflammatory 
sites, OXE-R signaling is supposed to be related to inflammatory diseases like asthma 
(Jones, 2005), cancer (Grant et al., 2009), and cardiovascular diseases (Grant et al., 
2009).    
An OXE-R antagonist would be of great advantage to evaluate the receptor´s role in 
inflammation and diseases related to inflammatory processes. To date, no synthetic 
small molecule OXE-R antagonist has been published. Until now, only endogenously 
formed OXE metabolites of the 12-LO pathway, such as 5-oxo-12-HETE or 8-trans-5-
oxo-12-HETE have been found to block OXE-mediated calcium mobilization in 
neutrophils, probably due to biological inactivation (Powell et al., 1999). Additionally, 
polyunsaturated fatty acids such as docosahexaenoic acid (DHA), eicosapentaenoic acid 
(EPA), dihomo-y-linolenic acid and eicosa-11Z,14U,17Z-trienoic acid have been 
reported to exhibit antagonistic activity against the OXE-R in GTPγS binding assays 
(Hosoi et al., 2002). 
1.6 Aim of this work 
The aim of this work was to discover small molecule OXE-R antagonists and to explore 
their antagonistic efficacy on the various signaling pathways of the OXE-R in a 
recombinant human cell line engineered to overexpress the receptor.  
Toward this goal, a number of functional assays had to be established allowing to 
monitor G protein-dependent and G protein-independent effector activation of the OXE-
R (calcium mobilization, cAMP inhibition, dynamic mass redistribution, β-Arrestin 
recruitment). The putative OXE-R antagonists should then be tested on endogenously 
expressed OXE-R in primary human eosinophils and neutrophils to determine their 
functionality in the receptor´s natural environment and to explore the consequences of 
OXE-R activation for primary cell function.  
The very aim of this work therefore was to carefully dissect the various OXE-R 
signaling pathways and to evaluate antagonistic efficacy of OXE-R inhibitors on all 
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pathways with the goal to identify a small molecule antagonist that is competent to 
inhibit OXE-R signaling in both recombinant and primary human cells and therefore 
serve as a valuable tool for studies on the pathophysiological role of the OXE-R in 
inflammatory diseases. 
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2 Material and methods 
2.1 Material 
2.1.1 Chemicals, enzymes and reagents 
5-oxo-6E,8Z,11Z,14Z-   Cayman, distributed by Biozol,  
eicosatetraenoic acid, 5-oxo-ETE  Eching, DE, #34250  
Agar      Fluka, Hamburg, DE, #05040 
Agarose UltraPure    Invitrogen™, Darmstadt, DE, #15510-27 
Ampicillin sodium salt   Roth, Karlsruhe, DE #K029.1  
Bovine serum albumin, fatty acid free Sigma, Taufkirchen, DE, #A6003 
Bromphenol blue    Fluka, Hamburg, DE, #32712 
Calcium chloride, dehydrate   Sigma, Taufkirchen, DE, #C3306  
Carbachol     Sigma, Taufkirchen, DE, #C4382 
Coelenterazine 400 a    Gold Biotechnology, St. Louis, USA, 
      #C-320-10 
compounds selected from  
virtual screening 
(ZINC codes depicted): 
- 682471      Molport, Riga, LT, #MolPort-002-826-987 
- 938141      Enamine, Kiev, UA, #T5398912 
- 1071153      Labotest, Niederschöna, D, #LT02891795 
- 1087122      Aronis, Moscow, RUS, #m09511 
- 3022900      Molport, Riga, LT, #MolPort-007-924-797 
- 9030109      Molport, Riga, LT, #MolPort-000-501-445 
- 9925404      UORSY, Kiev, UA, #PB-90138328 
- 11852816      Interchim, Montlucon cedex, F, 
      # F0817-0134 
Dextran T-500    Roth, Karlsruhe, DE, #9219.2 
Disodium hydrogen phosphate,  Roth, Karlsruhe, DE, #4984 
dihydrate 
Dimethyl sulfoxide    Riedel-de Haen, Seelze, DE, #60153 
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DNA ladder 1 kb    New England BioLabs®, MA, US,    
      #N3272    
Ethylenediaminetetraacetic acid,   Roth, Karlsruhe, DE, #8040.3 
disodium salt dihydrate  
Ethanol     KMF Optichem, Lohmar, DE, #08-205 
Forskolin     Tocris, Bristol, UK, #1099 
D-(+)-glucose     Sigma, Taufkirchen, DE #G7021 
Geneticin     Gibco, Paisley, UK, #11811 
HEPES     AppliChem, Darmstadt, DE,    
      #A1069.0500 
Hydrochloric acid    Applichem, Darmstadt, DE #0659 
Hygromycin B    Invivogen, Toulouse, FR, #ant-hm-1 
Interleukin-8     Peprotech, London, UK, #200-08M 
3-Isobutyl-1-methylxanthine   Tocris, Bristol, UK, #2845 
Magnesium chloride, hexahydrate  Fluka, Hamburg, DE, #63068  
Magnesium sulphate, heptahydrate  Applichem, Darmstadt, DE, #A10373 
(N-Morpholino)propanesulfonic acid Sigma, Taufkirchen, DE, #M-1254 
Nicotinic acid     Roth, Karlsruhe, DE, #3815.1 
Oregon Green® BAPTA-1/AM  Molecular Probes, Darmstadt, DE, 
      #O6807 
Pertussis toxin     Sigma, Taufkirchen, DE, #2980 
Pluronic®-F127    Molecular Probes, Darmstadt, DE,  
       #P6867 
Poly-D-Lysin     Sigma, Taufkirchen, DE, #P-6407 
Potassium acetate    Merck, Darmstadt, DE, #1.04820 
Potassium carbonate    Fluka, Hamburg, DE, #60110 
Potassium chloride    Fluka, Hamburg, DE, #60128 
Potassium dihydrogen phosphate  ZVE, D-53121 Bonn; #234984 
Prostaglandin D2     Cayman, MI, US, #12010 
Restriction endonucleases:   New England BioLabs®, MA, US 
-BamHI     #R0136S 
-EcoRI     #R0101S 
-HindIII     #R0104S 
-KpnI      #R0142S 
-XbaI      #R0145S 
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-XhoI      #R0146S 
Rubidium chloride    Merck, Darmstadt, DE, #107615  
Sodium acetate    Applichem, Darmstadt, DE, #4555 
Sodium chloride    Fluka, Hamburg, DE, #71376 
Sodium dihydrogen citrate, 99%  Sigma, Taufkirchen, DE, #234265 
Sodium dihydrogen phosphate  Roth, Karlsruhe, DE, #T878.2 
Disodium hydrogen phosphate  Roth, Karlsruhe, DE, #T876.2 
Sodium hydrogen carbonate   Merck, Darmstadt, DE, #1.06323.2500 
Sodium hydroxide    Fluka, Hamburg, DE, #71689 
Sulfuric acid     Merck, Darmstadt, DE, #1007311000 
Tris(hydroxymethyl)-aminomethane  Roth, Karlsruhe, DE, #5426 
Tryptone     Roth, Karlsruhe, DE, #8952.1 
Yeast extract     Applichem, Darmstadt, DE, #3732 
 
 
2.1.2 Kits 
Calcium 4 assay kit FLIPR      Molecular devices, CA, USA, #R8142 
cAMP dynamic 2 HTRF
®
 assay kit Cisbio Bioassays, BP 84175, France, 
      #62AM4PEC 
LANCE
®
 Ultra cAMP assay kit Perkin Elmer, Rodgau, DE, #TRF0262 
NucleoBond
®
 Xtra Maxi kit Macherey Nagel, Düren, DE, 
 #740414.50 
 
2.1.3 Devices 
Autoclave 3850 ELV, Systec 
 Brunswick Scientific, NJ 08818-4005, 
USA 
Balances TE64, Sartorius, Göttingen, DE 
 (precision balances) 
 TE6101, Sartorius, Göttingen, DE 
 (analytical balances) 
Cell counting chamber  Neubauer, Brand, Wertheim, DE 
Centrifuges MiniSpin, Eppendorf, Hamburg, DE 
 5810, Eppendorf, Hamburg, DE 
 6K10, Sigma, Osterode, DE 
12  2 Material and methods 
Dry block heater QBT2, Grant Instruments, Cambridge,
 UK 
Electroporation device  Gene Pulser Xcell™, BioRad®, CA, US 
Electrophoresis chambers Mini-Sub
®
 cell GT, Bio Rad, CA, USA 
 Wide Mini-Sub® cell GT, Bio Rad, CA,
 USA 
Freezer (-80°C) Herafreeze, Heraeus, Hanau, DE 
Incubator/shaker (bacteria) HT-INFORS, Buch+Holm, CH 
Incubator (cells) HERAcell 240, Thermo Fisher, Dreieich,
 DE 
Liquid nitrogen tank MVE-Tec 3000, GermanCryo, Jüchen,
 DE 
Microbiological safety cabinets S@fe flow 1.2, Nunc™, NY, USA 
Microplate readers NOVOstar
®
, BMG Labtech, Offenburg,
 DE 
Mithras LB940 Multimode reader  Berthold Technologies, Bad Wildbad,
 DE 
Microscope CKX31, Olympus, Hamburg, DE 
Microwave Microwave 800, Severin, Sundern, DE 
Pipettes Eppendorf, Hamburg, DE        
0.5-10 µl; 10-100 µl; 20-200 µl;            
100-1000 µl  
Pipettes, multichannel Alpha, Genex, Torquay, UK  
Power supply Power Pac HC, BioRad
®
, CA, US 
pH meter SevenEasy, Mettler Toledo, Giessen, DE 
Sterile bench (cell culture) HeraSafe, Thermo Fisher, Schwerte, DE 
Thermomixer Thermomixer
®
 comfort, Eppendorf,  
 Hamburg, DE 
Spectrophotometer Smart Spec Plus, BioRad
®
, CA, US 
Vortexer Reaxtop, Heidolph, Schwabach, DE 
Water purification system Milli Q
®
 Water system, Millipore, MA,
 US  
 
2.1.4 Buffers and solutions  
2.1.4.1 Commercially available buffers and solutions 
DMEM Invitrogen™, Darmstadt, DE, #41965039 
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DPBS without Ca
2+
 and Mg
2+
 Invitrogen™, Darmstadt, DE,  
 #14190-094 
 
FCS Sera Plus Pan Biotech GmbH, Aidenbach,  
    DE, #3702-P290616 
Glycerol Sigma, Taufkirchen, DE, #G2025 
HBSS buffer Invitrogen™, Darmstadt, DE, #14025 
Histopaque Sigma, Taufkirchen, DE, #1077    
 
MEM Invitrogen™, Darmstadt, DE,  
 #31095-029  
Penicillin/streptomycin solution Invitrogen™, Darmstadt, DE, #15140 
Sodium pyruvate MEM 100 mM          Invitrogen™, Darmstadt, DE,  
   #11360039 
Trypsin/EDTA 0.05/0.02% in PBS          Pan Biotech GmbH, Aidenbach, DE, 
   #P10-0231SP                                      
Ultra pure water  Invitrogen™, Darmstadt, DE, #10977035
      
2.1.4.2 Other buffers and solutions 
Aqua dem. was used as solvent unless otherwise stated. 
 
Assay buffer for DMR and BRET assays 
20 mM HEPES in HBSS, pH 7.2.  
 
CaCl2 solution for calcium phosphate transfection  
2 M CaCl2, filter-sterilised (0.2 µm). 
 
Coelenterazine stock solution 
1 mg Coelenterazine 400a resuspended in 2500 µl of 99.9% Ethanol (final conc. 1 mM). 
 
Coelenterazine reagent 
Coelenterazine stock solution diluted in BRET assay buffer containing 30% ethanol 
(final concentration 100 µM). 
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Competent bacteria buffer 1 
30 mM CH3COOK, 50 mM MnCl2 x 4 H2O, 100 mM CaCl2 x H2O, 15% glycerine, pH 
5.8, filter-sterilised (0.2 µm).  
Competent bacteria buffer 2 
10 mM RbCl, 75 mM CaCl2, 10 mM MOPS, 15% glycerine, pH 6.8, filter-sterilised 
(0.2 µm). 
 
DNA loading dye (6x) 
Bromphenol blue (0.25% w/v) in equivalent amounts of glycerol and deionized water. 
 
6% Dextran solution 
6% Dextran in 0.9% saline. 
 
Electroporation buffer (EB) (5x) 
250 mM K2HPO4, 100 mM CH3COOK, 100 mM KOH, pH 7.4 with acetic acid, filter-
sterilised (0.2 µm). 
 
HEPES solution (1 M) 
1 M HEPES, pH 7.2, filter-sterilised (0.2 µm). 
 
Hepes bufferd saline (HBS) (2x) for calcium phosphate transfection 
50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.1, filter-sterilised (0.2 µm). 
 
Krebs-HEPES-buffer (KHB) 
118.6 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 4.2 mM NaHCO3, 11.7 mM D-
glucose, 10 mM HEPES, making a 5x concentrated buffer stored at -20°C. Dilution of 
5x KHB buffer with deionized water to 1x, then addition of 1.3 mM MgSO4 and 1.2 
mM CaCl2, pH 7.4 with 1 M sodium hydroxide. 
 
Luria Bertani (LB) medium  
1%  bactotryptone, 0.5% yeast extract, 1% NaCl, pH 7.4, sterilised by autoclaving at 
121°C. 
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MgSO4 solution for electroporation 
1 M MgSO4 heptahydrate, filter-sterilised (0.2 µm). 
 
Neutrophil washing buffer 
PBS without Ca
2+
 and Mg
2+
, 10 mM HEPES, 10 mM Glucose, 0.1% BSA fatty acid 
free, pH 7.4. 
  
Neutrophil DMR assay buffer 
PBS with Ca
2+
 and Mg
2+
, 10 mM HEPES, 10 mM Glucose, 0.1% BSA fatty acid free, 
pH 7.4. 
 
Oregon Green
®
 stock solution  
39.7 µl DMSO were added to 50 µg Oregon Green
®
 488 BAPTA-1/AM (final 
concentration 1 mM), 3 µl aliquots of 1 mM stock were stored at -20°C under exclusion 
of light. 
 
Oregon Green
®
 assay solution 
A 3 µl aliquot of Oregon Green
®
 stock solution (1 mM) was diluted in 1994 µl KHB 
and 3 µl 20% pluronic
®
-F-127. 
 
Phosphate buffered saline (PBS)  
150 mM NaCl, 2.5 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 with HCl, 
sterilised by autoclaving at 121°C. 
 
3.8% sodium citrate 
3.8% sodium citrate, filter-sterilised (0.2 µm), stored at 4°C.  
 
Stimulation buffer for HEK293 cell cAMP assays (cAMP dynamic 2 HTRF® assay 
kit) 
HBSS, 20 mM HEPES, 1 mM 3-isobutyl-1-methylxanthine (IBMX). 
 
Stimulation buffer for neutrophil cAMP assays (LANCE
®
 Ultra cAMP assay kit)  
HBSS, 5 mM HEPES, 0.5 mM IBMX, 0.1% BSA, pH 7.4, according to LANCE
®
 Ultra 
assay development guidelines. 
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Super optimal broth (SOB) 
2% Bactotryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, pH 7.4,  
sterilised by autoclaving at 121°C. After autoclaving 1 ml of sterile 1 M MgCl2 and 1 
ml of sterile 1 M MgSO4 were added to 100 ml media.  
 
Tris acetate EDTA (TAE) buffer (50x) 
40 mM Tris(hydroxymethyl)-aminomethane (Tris), 1 mM EDTA, 5.71% glacial acetic 
acid. Diluted 1:50 before use. 
 
Tris-EDTA (TE) buffer  
10 mM Tris, 1 mM EDTA, pH 8.0 with HCl, filter-sterilized (0.2 µm).  
 
2.1.5 Consumables 
Cell culture plastic ware: 
- Plates: 6, 24, 48, 96 well  Corning
®
, NY, US, #3506, 3512, 3548, 
3596 
- Flasks: 25, 75 and 175 cm
2
  Corning
®
, NY, US, #430168, 430720, 
431079 
- Dishes: 6, 10 and 15 cm  Corning
®
, NY, US, #430161, 430167, 
430599 
Cryogenic vials 1.5 ml                                       Nalgene, Thermo Fisher Scientific, NY, 
                                                                    USA, #5012 
Falcon tubes 15 and 50 ml Corning
®
, NY, US 
Gene Pulser cuvette, 0.4cm,  BioRad
®
, CA, US, #1652088 
Microplates: 
- 384-well, fibronectin-coated Corning
®
, NY, US, #5042 
biosensor cell assay microplate (Epic
®
) 
- 384-well, biosensor cell assay  Corning
®
, NY, US, #5040 
microplate (Epic
®
) 
- 384-well, source plate (Epic
®
)   Corning
®
, NY, US, #3657 
- 384-well, LIA-plate, white, TC, F-form Greiner, Frickenhausen, DE, #632102  
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Greiner bio one 4550 (cAMP assays) 
- 96-well, clear flat bottom, costar cell plate Corning
®
, NY, US, #3599 
(Calcium mobilization assay) 
- 96-well, v-bottom, costar plate Corning
®
, NY, US, #3357 
(Calcium mobilization assay) 
- 96-well, round bottom, costar plate Corning
®
, NY, US, #3795 
(Calcium mobilization assay) 
- 96-well, flat bottom, white,  Perkin Elmer, Rodgau, DE, # 6005500  
Optiplate (BRET) 
Norm-Ject, sterile single-use  Henke Sass Wolf, Tuttlingen, DE 
syringe 20 ml (24 ml)  #4200.000VE 
Petri dishes (for bacteria) Greiner, Frickenhausen, DE, #632102 
reaction tubes 1,5 ml and 2,0 ml Eppendorf, Hamburg, DE 
Pipet tips Sarstedt, Nümbrecht, DE 
Tiptrays 384 (for Epic
®
) CyBio, Jena, DE, #3800-25-513-N 
Venofix winged infusion set,                         B.Braun, Melsungen, DE, #4056337 
Luer Lock 21G 
 
2.1.6 Software 
Citavi 3.0  Swiss Academic Software GmbH,  
  Zürich, CH 
Office Excel
®
 2003         Microsoft Corporation,    
  Unterschleißheim, DE 
Office PowerPoint
®
 2003                           Microsoft Corporation,   
 Unterschleißheim,  DE 
Office Word
®
 2003                                    Microsoft Corporation,   
 Unterschleißheim, DE 
Prism
®
 4.02          GraphPad Software, Inc, CA, USA 
MicroWin 2000 AdvII v4.41      Mikrotek Laborsysteme GmbH, Overath, 
  DE 
DeVision G v1.0          Decon Science Tec GmbH,   
  Hohengandern, DE 
Assay Development Mode Epic™          Corning® Incorporated, NY, USA 
V1.22.2 
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Microplate Analyzer v1.5           Corning® Incorporated, NY, USA 
modified for Excel 2002 
NOVOstar
®
 1.20-0          BMG LABTECH, Offenburg, DE 
 
2.1.7 Bacteria 
XL1blue (Stratagene, CA, US), Escherichia coli, genotype: recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)] 
 
2.1.8 Vectors 
pcDNA3.1+ 
pcDNA3.1+ was purchased from Invitrogen
TM
, Darmstadt, DE, #V790-20 
 
OXE-R cDNA in pcDNA3.1+ 
cDNA of OXE-R R527 (GenBank accession-number NM_148962) was inserted into 
pcDNA3.1+ by HindIII and EcoRI restriction sites. The plasmid originated from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. 
 
HM74A cDNA in pcDNA3.1+ 
cDNA of HM74A (GenBank accession-number NM_177551) was inserted into 
pcDNA3.1+ by HindIII and EcoRI  restriction sites. The plasmid originated from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. 
 
RLuc cDNA in pcDNA3.1+ 
cDNA of Renilla Luciferase (GenBank accession-number M63501) was inserted into 
pcDNA3.1+ by BamHI and XbaI restriction sites. The plasmid originated from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. 
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OXE-R cDNA in pcDNA3.1+-RLuc 
cDNA of OXE-R R527 (GenBank accession-number NM_148962) was inserted into 
pcDNA3.1+-RLuc by HindIII and XbaI restriction sites. The plasmid originated from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. 
 
HM74A cDNA in pcDNA3.1+-RLuc 
cDNA of HM74A (GenBank accession-number NM_177551) was inserted into 
pcDNA3.1+-RLuc by HindIII and XbaI restriction sites. The plasmid originated from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. 
 
 
2.1.9 Mammalian cell lines 
HEK293 cells 
The used HEK293 cell line was from an internal source: research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceutical Biology, University of Bonn, Germany. 
 
HEK293 cells stably expressing OXE-R R527 and Gα subunit G16 (HEK293-OXE-
R-G16) 
HEK293 cells stably expressing OXE-R R527 and the Gα subunit G16 were from an 
internal source: research group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical 
Biology, University of Bonn, Germany. Cells include cDNA of OXE-R R527 (gene 
bank accession-number NM_148962) and cDNA of the Gα subunit of human G16. Cells 
were selected by resistance towards geneticin (G418) and hygromycin B. 
 
HEK293 cells stably expressing GFP
2
-labeled
 β-Arrestin2 (HEK-βARR2-GFP2) 
HEK293 cells stably expressing GFP
2
-labeled
 β-Arrestin2 and were kindly provided by 
Jesper Mosolff Mathiesen, University of Copenhagen, Copenhagen, Denmark.   
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HEK293 cells stably expressing GFP
2
-labeled
 β-Arrestin2 and CRTH2 fused to 
Renilla luciferase (HEK-βARR2-GFP2-CRTH2-Rluc) 
HEK293 cells stably expressing GFP
2
-labeled
 β-Arrestin2 and CRTH2 fused to Renilla 
luciferase were kindly provided by Jesper Mosolff Mathiesen, University of 
Copenhagen, Copenhagen, Denmark.   
 
HEK293 cells stably expressing CRTH2 (CRTH2-HEK) 
The HEK293 cell line stably expressing CRTH2 was from an internal source: research 
group of Prof. Dr. Evi Kostenis, Institute of Pharmaceutical Biology, University of 
Bonn, Germany. Cells include cDNA of CRTH2 (gene bank accession-number 
NM_004778) fused to a FLAG-tag at the N-terminus. Cells were selected by resistance 
towards geneticin (G418). 
2.2 Methods 
2.2.1 Molecular biology protocols 
2.2.1.1 Preparation of LB plates 
LB was prepared as described in section 2.1.4.2 and 1.5% (w/v) agar was added. The 
mixture was autoclaved and allowed to cool to 50°C prior to the addition of ampicillin 
(100 μg/ml). The medium was mixed to ensure equal distribution of antibiotic and ap-
proximately 25 ml were poured per 10 cm petri dish. The plates were left at room 
temperature before being stored at 4°C. 
 
2.2.1.2 Preparation of competent bacterial cells 
E. coli K12-XL-blue cells were streaked onto an LB agar plate in the absence of antibi-
otics and incubated overnight at 37°C. A single colony was inoculated into a 5 ml cul-
ture of SOB and grown at 37°C in a shaking incubator at 220 rpm for 16 hours. 1 ml of 
this culture was used to inoculate 100 ml SOB. The cell suspension was grown at 37°C 
and 220 rpm until the optical density at 550 nm reached the value of 0.5. The culture 
was centrifuged in ice-cold falcons for 10 min (3000xg, 4 °C). For the following work 
steps, chilled tips and falcons were used. The cell pellet was resuspended in 2x 12.5 ml 
ice-cold competent bacteria buffer 1 and centrifuged for 10 min (3000xg, 4 °C). After 
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cell pellet resuspension in 8 ml competent bacteria buffer 2, bacteria were aliquoted to 
100 µl, frozen in liquid nitrogen and stored at  80°C until required. 
 
2.2.1.3 Transformation of competent bacterial cells 
An aliquot of competent bacteria was allowed to thaw on ice. 100 ng of DNA were 
added and cells were incubated on ice for 20 minutes. Hereafter, cells were subjected to 
a heat shock at 42°C for 90 seconds and returned on ice for 2 minutes. For recovery and 
expression of the antibiotic resistance gene needed for positive selection of trans-
formants, 500 μl of LB without antibiotic was added to the cells and cell suspension was 
incubated at 37°C for 45 minutes in a shaking incubator. 100 μl of the cell suspension 
was spread onto LB plates containing the appropriate selective antibiotic and plates 
were incubated overnight at 37°C.  
 
2.2.1.4 Preparation of glycerol stocks from transformed bacteria 
A single colony of transformed E. coli cells grown on a LB plate overnight (see 2.2.1.3) 
was picked with a sterile wooden stick and transferred into 5 ml or larger amounts of 
LB media containing the appropriate antibiotic. The cell suspension was incubated 
overnight at 37°C in a shaking incubator at 200 rpm. The overnight culture was supple-
mented with glycerol to 15%  and stored in a cryovial at –80°C. 
 
2.2.1.5 Preparation of plasmid DNA 
A 200-500 ml culture of transformed bacteria was pelleted by centrifugation at 7000 
rpm at 4°C for 15 min. DNA was isolated with the NucleoBond® Xtra Maxi kit (2.1.2) 
according to the manufacturer´s instructions.  
 
2.2.1.6 Digestion of DNA with restriction endonucleases  
Digests were performed with 500 ng DNA, 0.5 µl of the appropriate restriction enzyme, 
2 µl of the appropriate buffer specified by the manufacturer, BSA if required, and puri-
fied water (UltraPure, Invitrogen®) in a total volume of 20 µl. Reactions were 
incubated at 37°C for a minimum of 2 hours and heat-inactivated for 15 min at 70°C. 
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2.2.1.7 DNA gel electrophoresis 
Digested DNA samples were examined using gel electrophoresis. Samples were diluted 
in 5-fold concentrated DNA loading buffer. A 0.7% agarose gel was prepared by mixing 
agarose with 1x TAE and boiling the solution in a microwave until the agarose was 
completely melted. After the solution was cooled down to 60 °C, 2.5 mg/ml ethidi-um 
bromide was added. The gel was set in a horizontal gel tank and immersed in 1x TAE. 
Samples and 1 kb DNA marker were loaded and the gel ran at a voltage of 100 V for 
30-40 minutes. The DNA fragments were visualised using ultraviolet light and the size 
of each fragment was assessed by comparison with 1 kb DNA marker. Pictures were 
taken with the photo documentation system DeVision G v1.0. 
 
2.2.1.8 Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance of a 1:100 
dilution of the sample at 260 nm. An A260 value of 1 unit was taken to correspond to 
50 μg/ml of double stranded DNA. The A280 value of sample was also measured to 
assess the purity of the DNA solution. A DNA solution with A260/A280 ratio between 
1.7 and 2.0 was considered pure enough for use. 
 
2.2.2 Cell culture protocols 
2.2.2.1 Cell culture media 
Medium for HEK293 cells 
HEK293 cells were cultivated in Dulbecco's Modified Eagle's Medium (DMEM,) 
supplemented with 10% (v/v) fetal calf serum (FCS), 100 U/ml penicillin and 100 
µg/ml streptomycin. 
 
Medium for HEK-OXE-R-G16 cells 
HEK-OXE-R-G16 cells were cultivated in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 20% (v/v) fetal calf serum (FCS), 400 µg/ml of geneticin 
418 (G418) and 250 µg/ml hygromycin B. 
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Medium for HEK–βARR2-GFP2 cells 
HEK-βARR2-GFP2 cells were cultivated in Dulbecco's Modified Eagle's Medium 
(DMEM,) supplemented with 10% (v/v) fetal calf serum (FCS), 100 U/ml penicillin, 
100 µg/ml streptomycin and 500 µg/ml of geneticin 418 (G418). 
 
Medium for CRTH2-HEK cells 
CRTH2-HEK cells were cultivated in DMEM supplemented with 10% (v/v) FCS, 100 
U/ml of penicillin, 100 µg/ml of streptomycin and 500 µg/ml of geneticin 418 (G418). 
 
2.2.2.2 Cell maintenance 
Human embryonic kidney cells (HEK293) were grown in an incubator of 5% CO2 and 
95% air humidity at 37°C. Cells were grown in flasks or plates of varying sizes 
depending on the requirement of cells. 
 
2.2.2.3 Passage of cells 
For dividing confluent HEK293 cells, medium was removed, sterile PBS was added to 
wash the cells and removed. Sterile 0.25% Trypsin was added and flasks were placed in 
the incubator for 3 minutes. Fresh medium was then directly added to the detached cells 
and the cells were replated at desired density in new flasks or dishes. 
 
2.2.2.4 Thawing and freezing cells 
Liquid nitrogen frozen cells were thawed in a water bath at 37ºC. Cells were 
immediately transferred to a 15 ml falcon containing 4 ml of warm medium. The cell 
suspension was pelleted at 800 rpm for 4 min, the supernatant was discarded and the 
cells were resuspended in medium and transferred to an appropriate culture flask or 
dish.  
To freeze cells, cells were washed, trypsinised, counted and pelleted at 800 rpm for 4 
min. The medium was discarded and cells were resuspended with an appropriate 
amount of freezing solution (90% FCS, 10% DMSO) so that cell density was 3x10
6
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cells/ml. Cells were transferred to a cryogenic vial and placed at -80ºC overnight. The 
next day, cells were transferred to liquid nitrogen for long term conservation. 
 
2.2.2.5 Cell count 
20 µl of a cell suspension were pipetted between the surface of a counting chamber and 
a cover slip. The cell number of one big square was counted. The cell density and the 
total cell number was determined by the following terms:  
Cell density [cells/ml] = counted cells x dilution factor x 10
4
 
Total cell number = cell density x volume [ml] 
 
2.2.2.6 Transient cell transfection via calcium phosphate-DNA co-precipitation 
24 hours prior to transfection, cells were seeded at 4x10
6 
cells per 10 cm dish in DMEM 
10% FCS to achieve 70-80% confluence at the time of transfection. The day of 
transfection, medium was exchanged with 10 ml of fresh medium (DMEM, 10% FCS). 
20 µg of DNA was mixed directly with 60 µl 2 M CaCl2 and filled up with TE (10 mM 
Tris-HCl, 1 mM EDTA, pH 7.5) to a final volume of 500 µl. This was added dropwise 
to a volume of 500 µl 2x HBS buffer (50 mM HEPES, 280 mM NaCl, 1.5 mM 
NaH2PO4, pH 7.2) at minimum speed for vortex. After incubation for 45 min at room 
temperature, the mixture was added dropwise to the cells. The medium was changed 
after 16 hours to avoid cell toxic effects. In the present work, the total DNA amount 
consisted of 1:1 receptor DNA and empty vector.  
 
2.2.2.7 Transient cell transfection via electroporation 
For BRET assays (2.3.3), pcDNA3.1(+)-OXE-R-Rluc was introduced into stable 
HEK293-GFP
2
-bARR2 cells using the Gene pulser Xcell™ electroporator. 1 µg 
receptor construct and 4 µg pcDNA3.1(+) were mixed with 20 µl 5x electroporation 
buffer (EB) and 4 µl of 1 M MgSO4. Afterwards solution was filled up to a final volume 
of 100 µl with aqua dem. HEK293-GFP
2
-βARR2 cells were trypsinised, counted and 
pelleted per 5 Mio cells. The pelleted cells were resuspended in 30 µl of 1x EB, cells 
were added to the DNA buffer mix and incubated at room temperature for 10-15 min. 
Cells were transferred to a 4 mm electroporation cuvette and electroporation was carried 
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out in the electroporator at 250 V, 500 µF and ∞ Ω. After electropration, cells were 
removed from the cuvette without cell debris and resuspended in media without 
antibiotics. Cells were grown for 48 hours prior to the assay. 
 
2.2.2.8 Isolation of neutrophils from human peripheral blood 
Peripheral blood from healthy volunteers was collected according to a protocol 
approved by the Ethics Committee of the medical faculty of the University of Bonn. All 
volunteers provided informed consent. 20 ml of blood were added to 4.4 ml 3.8% 
sodium citrate in a 50 ml falcon (fig. 3).  
 
Figure 3: 20 ml of human peripheral blood supplemented with 4.4 ml 3.8 % sodium     
citrate. 
 
Immediately, the falcon was gently inverted to prevent blood coagulation. To remove 
platelet-rich plasma, the blood was centrifuged at 400xg without brake at room 
temperature for 20 min. After centrifugation, two phases were obtained: an upper 
plasma phase and a lower phase containing blood cells (fig. 4). The plasma was 
carefully discarded without touching a white interphase between plasma and blood cells 
containing leukocytes. 
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Figure 4: Separation of plasma from blood cells.  
For dextran sedimentation of erythrocytes and platelets, 6 ml of 6% dextran was added 
and the falcon was filled up to 50 ml with 0.9% saline. After gentle shaking, the inside 
of the falcon lid was cleaned, bubbles were taken out and the falcon was incubated at 
room temperature for 30 min. Erythrocytes sedimented to the bottom of the falcon and 
leucocytes remained in the upper phase (fig. 5). 
 
Figure 5: Dextran sedimentation of erythrocytes. 
The leukocyte upper phase obtained from dextran sedimentation was carefully placed 
onto 15 ml of Histopaque
®
 (fig. 6) and centrifuged at 400xg without brake for 20 min at 
room temperature.  
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Figure 6: Leukocyte phase layered onto 15 ml of Histopaque
®
 
After centrifugation, five phases were obtained (from the top to the bottom, fig. 7): 
saline (yellow), peripheral blood mononuclear cells (PBMCs, white) including 
monocytes, basophils and lymphocytes, Histopaque
®
 (white transparent), 
polymorphonuclear leukocytes (PMNL, light red) containing eosinophils and 
neutrophils and red blood cells (RBC, dark red). 
 
Figure 7: Polymorphonuclear cells are separated from peripheral blood mononuclear cells 
after Histopaque
®
 density gradient centrifugation.  
 
The saline, the PBMC and the Histopaque phase were discarded and the remaining 
PMNL pellet was resuspended in 10 ml wash buffer. The cells were pelleted at 400xg 
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with maximum brake for 7 min (fig. 8) and haemolysis was carried out to remove the 
remaining red blood cells from the leukocytes.  
 
Figure 8: Cell pellet of leukocytes containing red blood cells 
Thereforee, the supernatant was discarded, the pellet was resuspended in 1 ml 0.2% 
saline, and immediately 10 ml of 1.6% saline were added. After addition of further 10 
ml washing buffer, cells were centrifuged at 400xg with maximum brake for 7 min. The 
supernatant including disrupted erythrocytes was discarded, the remaining neutrophils 
were washed twice with 10 ml wash buffer and cells were counted in a cell chamber 
(section 2.2.2.5). With this method, cell purity was 98% with the majority of 
contaminating cells being eosinophils.  
 
2.2.3 Cell based assays 
2.2.3.1 Calcium mobilization assay 
Calcium mobilization assay principle and protocol 
Calcium release from intracellular stores is triggered by Phospholipase C activation 
followed by Inositol phosphate 3 accumulation, which triggers calcium release from the 
endoplasmic reticulum. For detection of released calcium, cells are loaded with a cell 
membrane permeable dye. Intracellular esterases convert the dye into its active form. 
Released calcium is bound to the dye and the fluorescence properties of the dye change.   
Calcium measurements were performed using a NOVOstar
® 
microplate reader with a 
built-in pipetor (BMG Lab Tech, Offenburg, Germany). 
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24 hours prior to the assay, cells were detached, counted and seeded into a PDL-coated 
96-well plate at a cell number of 50.000 cells/well for transiently transfected cells and at 
a cell number of 60.000 cells/well for stable cells, and cells were incubated overnight at 
37°C in a 5% CO2 atmosphere. On the day of the assay, cells were washed twice with 
50 µl KHB-buffer, and 20 µl Oregon Green
®
 488 BAPTA-1/AM or 50 µl of Ca4 
solution, respectively, were added to each well. Cells were incubated at 37° and 5% 
CO2 for 60 min. Meanwhile, 10-fold concentrated agonist was added to the 96-well 
agonist plate. KHB was added to the cells up to a final volume of 180 µl per well. Both 
the test and compound plate were transferred to the NOVOstar
®
 and kept at 37°C under 
exclusion of light for 15 min until the measurement was started. The gain of the test 
plate was determined. For agonist assays, 20 µl compound solution was injected 
sequentially per well and fluorescence intensity was monitored at 520 nm (bandwith 20 
nm) for 25 seconds at 0.4 s intervals. Excitation wavelength was 485 nm (bandwidth 25 
nm). Antagonist assays were performed by addition of agonist after pre-incubation with 
antagonist for 30 min at 37 °C. The maximum fluorescence intensity was determined 
for each data set, and the mean value of a triplicate was plotted against agonist or 
antagonist concentration, respectively using GraphPad Prism
®
. Dose response curves 
were generated by a non-linear sigmoidal fit.  
 
2.2.3.2 cAMP accumulation assays 
In cAMP accumulation assays, the Gi mediated inhibition of forskolin-stimulated 
adenylyl cyclase of the OXE receptor was analysed by measuring cAMP production. 
For experiments with HEK293-OXE-R-G16 cells, the HTRF
®
-cAMP dynamic 2 kit 
from Cisbio was used, and for neutrophil cAMP accumulation assays, the LANCE
®
 
Ultra cAMP kit from Perkin Elmer was used.  
 
HTRF
®
-cAMP dynamic 2 assay principle and protocol 
The HTRF
®
-cAMP dynamic 2 assay is based on time-resolved resonance energy 
transfer (HTRF
®
) using a competition immunoassay where cellular cAMP competes 
with a labeled form of cAMP for binding to an anti-cAMP antibody. The anti-cAMP 
antibody used as donor is labeled with europium cryptate, and cAMP labeled to the dye 
d2 is used as acceptor.   
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Light excitation (320 nm) at anti-cAMP conjugates leads to emission of light (620 nm). 
When the cAMP-d2 molecule binds to the anti-cAMP conjugate, fluorescence 
resonance energy transfer (FRET) between the europium cryptate and the dye d2 
occurs, resulting in fluorescence caused emission of light (655 nm). Results are 
calculated from the ratio of absorbance at 665 nm/620 nm. Obtained ratio values are 
corrected by a negative control, consisting of buffer and europium cryptate, and 
calculations are performed according to following formula: 
 
Due to the inverse relationship between signal and cAMP concentration, accumulation 
of cAMP will result in a decreased signal.  
HEK-OXE-R-G16 cells were detached, counted and resuspended in stimulation buffer at 
a cell number of 10
6
/ml. Cells were dispersed into a 384-well microplate at a density of 
50.000 cells per well (5 µl), briefly centrifuged and incubated at 37°C for 30 min. For 
agonist assays, cells were stimulated with 5 µl compound solution consisting of 2.5 µl 
4-fold concentrated agonist or buffer, respectively, and 2.5 µl 4-fold concentrated 
forskolin and incubated for 30 min at 37°C. For antagonist assays, cells were incubated 
with 2.5 µl antagonist solution 4-fold concentrated or buffer, respectively, for 30 
minutes at 37 °C, followed by stimulation with 2.5 µl compound solution consisting of 
1.25 µl 8-fold concentrated agonist or buffer, respectively, and 1.25 µl 8-fold 
concentrated forskolin. After agonist stimulation, reactions were stopped by addition of 
5 µl lysis buffer containing anti-cAMP conjugate and 5 µl lysis buffer containing 
cAMP-d2. The cell plate was incubated for 60 min at room temperature, and time-
resolved FRET signals were measured at an excitation wavelength of 320 nm using the 
Mithras LB 940 multimode reader. 
Data was analysed using the fluorescence ratio of light emitted by d2 labeled cAMP at 
665 nm over light emitted by europium cryptate-labeled anti-cAMP at 620 nm. Levels 
of cAMP were normalised to the amount of cAMP elevated by 0.5 µM forskolin. 
 
 
Delta F =                                              * 100        
Ratiosample - Rationeg 
Rationeg 
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LANCE
®
 Ultra cAMP assay principle and protocol 
The LANCE Ultra cAMP assay is a homogeneous time-resolved fluorescence 
resonance energy transfer (TR-FRET) immunoassay where sample cAMP competes 
with Europium chelate-labeled cAMP for binding to anti-cAMP antibody labeled with 
ULight™ dye. When antibodies are bound to the Eu-labeled tracer and a light pulse at 
320-340 nm excites the europium chelate molecule of the tracer, energy is emitted and 
transferred by FRET to ULight
TM
 molecules on the antibody, which in turn emit light at 
665 nm. Residual energy from the europium chelate will produce light at 615 nm. Data 
is expressed as ratio of emitted light at 665 nm and 615 nm as described by the 
following term:  
Ratio (665/615*10
4
) 
 
In the absence of free cAMP, maximal HTRF signals at 665 nm are obtained, whereas 
when native, free cAMP competes with the Eu-cAMP tracer for binding to the 
ULight
TM
-labeled antibodies, a decrease in HTRF signals at 665 nm is measured.  
Neutrophils were resuspended in neutrophil stimulation buffer, seeded into a 384-well 
microplate at a density of 12.000 cells per well (5 μl) and briefly centrifuged. For 
agonist assays, cells were incubated with 5 μl agonist solution, consisting of 2.5 μl 4-
fold concentrated agonist and 2.5 μl 4-fold concentrated forskolin solution. After 30 
min, 5 μl 4-fold concentrated Eu-cAMP tracer working solution and 5 μl ULight-anti-
cAMP working solution were added, and the plate was incubated at room temperature 
for 1 h. Fluorescence signals at 665 and 615 nm were detected using the Mithras LB 
940 multimode reader (Berthold Technologies).  
For antagonist assays, seeded cells were incubated with 2.5 μl 4-fold concentrated 
antagonist solution for 15 minutes before adding 2.5 μl of 4-fold concentrated agonist 
solution, consisting of 1.25 μl 8-fold concentrated agonist and 1.25 μl 8-fold 
concentrated forskolin solution.   
 
Data derived from cAMP accumulation assays were collected using the MicroWin2000 
software (Berthold Biotechnologies) and GraphPad Prism
®
 software was used for dose 
response curves fitted with nonlinear regression and sigmoid dose-response equation. 
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2.2.3.3 BRET assay 
BRET assay principle and protocol 
Bioluminescence resonance energy transfer (BRET) technology is a proximity assay, 
based on non-radiative transfer of energy between a bioluminescent donor and a 
fluorescent acceptor. Fluorescence can only be measured if energy donor and acceptor 
moieties are less than 100 Å apart. The enzyme Renilla luciferase (Rluc) is used as 
bioluminescent donor and the chromophore GFP (Green Fluorescent Protein) as 
complementary fluorescent acceptor. BRET is monitored in real time and can be 
measured in living cells. If luciferase and GFP are attached to two proteins, e.g. the 
luciferase to a receptor and GFP to β-Arrestin2 (βARR2), the occurence of BRET can 
be taken as a result of the interaction of these two proteins.  
Upon oxidation of a coelenterazine substrate by the luciferase, blue light is emitted 
which overlaps with the excitation spectrum of GFP, which then produces green light. 
There are different coelenterazine substrates to be used for different BRET techniques 
(Pfleger et al., 2006). In the present work, BRET
2
 was utilized with Coelenterazine 400 
a (also known as DeepBlueC) as luciferase substrate and GFP
2
 as fluorescent acceptor. 
Oxidation of Coelenterazine 400 a results in an emission peak at 400-420 nm that exites 
GFP
2
 producing light emission with a peak at around 510 nm. The BRET signal is 
determined by monitoring the ratio of green light (515 nm) over blue light (410 nm).  
HEK293 cells stably expressing GFP
2
 linked to βARR2 were electroporated with the 
OXER(R527)-Rluc construct. 48 h after transfection, cells were detached, counted and 
washed with assay buffer. Cells were resuspended in assay buffer at a cell number of 
10
6
/ml and incubated at 28°C with shaking at 160 rpm for at least 30 min. 10 µl 19-fold 
concentrated agonist or buffer were added to a white 96-well plate. Cells were added to 
agonist with a cell density of 180.000/well and incubated at 300 rpm for 10 min. 10 µl 
of 100 µM Coelenterazine 400 a was injected automatically by the Mithras and readings 
were collected immediately.  
For antagonist assays, cell number was adjusted to 1.059x10
6
/ml. 10 µl 19(or 18)-fold 
concentrated antagonist were added to a white 96-well plate, cells were added and 
incubated at 300 rpm for 30 min. 10 µl 19-fold concentrated agonist were added and 
cells were incubated at 300 rpm for another 10 min before measurement.  
Data were collected using the MicroWin2000 software (Berthold Biotechnologies) and 
BRET signal was expressed in mBRET units of BRET ratio. GraphPad Prism
®
 software 
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was used for dose response curves fitted with nonlinear regression and sigmoid dose-
response equation. 
 
GFP
2
 control 
150 µl assay buffer and 50 µl of suspended cells per well were added to a black 96-well 
plate, which was incubated at room temperature for 60 min. GFP
2
 fluorescence was read 
by the Mithras with excitation wavelength of 400 nm and emission wavelength of 515 
nm. 
 
RLuc control 
140 µl assay buffer per well was added to a white 96-well plate. 50 µl of suspended 
cells per well were added and cell suspension was incubated at room temperature for 60 
min. 10 µl of 100 µM Coelenterazine 400 a per well were injected by the Mithras and 
RLuc luminescence was read immediately at emission wavelength of 400 nm for 10s. 
 
2.2.3.4 Dynamic mass redistribution (DMR) assays 
DMR assay principle and protocol 
DMR assays were performed using a beta version of the Corning
®
 Epic
®
 System 
consisting of a temperature-control unit, an optical detection unit and an on-board 
robotic liquid handling device. The DMR assay is a holistic method which monitors 
GPCR-mediated cellular responses in real time and which is able to detect complex 
GPCR signaling (Fang et al., 2007; Schröder et al., 2010;). In this assay, changes in the 
local index of refraction upon mass redistribution within a cell monolayer grown onto a 
surface of a biosensor are measured. Cells are cultivated in a 384-well Epic
®
 microplate 
containing a resonant waveguide grating biosensor in the bottom of each well. 
Broadband light illuminates the biosensor, and light of a given wavelength is guided to 
travel parallel to the bottom of the well. The light extends for a depth of 150 nm into the 
adjacent cells, is reflected and the wavelength of the reflected light is measured. Within 
the cell, mass movement of signaling molecules or cytoskeleton rearrangement due to 
ligand-induced G-protein signaling appears. This leads to a change of local optical 
density affecting the passing light, resulting in a wavelength shift of the reflected light. 
The magnitude of this wavelength shift is proportional to the amount of DMR, and 
34  2 Material and methods 
increase of mass contributes positive and decrease negative to the overall DMR 
response.  
24 hours prior to the assay, cells were seeded at a cell number of 20.000/well in 30 µl 
medium onto fibronectin-coated 384-well Epic
®
 biosensor microplates and centrifuged 
for 5 s at 200xg. Cells were cultivated (37°C, 5% CO2) to obtain confluent monolayers. 
1 hour before the assay, cells were washed twice with HBSS containing 20 mM HEPES 
(DMR assay buffer) by aspirating the medium with an eight channel manifold with 10 
µl buffer remaining in each well. Cells were washed with 30 µl of assay buffer added to 
each well. In case the compound solutions contained dimethyl sulfoxide (DMSO), cells 
were washed in assay buffer containing the same percentage of DMSO as the later 
added compounds, because DMSO can induce bulk refractive index differences. After 
the last aspiration, the total volume was set to 30 µl by adding 20 µl of assay buffer. The 
microplate was centrifuged at 200xg for 5 s and kept for at least 1 hour in the Epic
®
 
reader at a constant temperature of 28°C. 
Neutrophils were seeded at a cell number of 70.000/well in 30 µl of assay buffer onto 
fibronectin-coated Epic
®
 biosensor microplates and centrifuged for 5 s at 200xg. The 
plate was directly transferred into the Epic
®
 reader and incubated for approximately 2 
hours. 
For compound addition, a 384-well source plate was prepared by loading 20 µl per well 
of 4-fold concentrated substance solutions and hereafter was kept in the Epic
®
 reader for 
at least 1 h prior to the assay. If antagonists were added in a first addition, a separate 
antagonist compound plate was prepared with 20 µl 5-fold concentrated antagonist per 
well, which was also pre-incubated for 1 hour in the Epic
®
 reader. For the second 
addition of agonist hereafter, the agonist compounds were prepared in 5-fold 
concentration. 
After starting the assay, the sensor plate was scanned and a baseline optical signature 
was recorded for 300 s. 10 µl of compound solutions were then transferred into each 
well of the sensor plate by an on-board liquid handling device and DMR was monitored 
for at least 3600 seconds. 
Data were collected using Microplate Analyzer v1.5 (Corning® Incorporated). For 
quantification of DMR responses in dose response curves, the maximum response value 
within the time line from 500-1800 s was used.  Dose response curves were established 
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with the GraphPad Prism
®
 software and curves were fitted with a nonlinear regression 
and sigmoid dose-response equation. 
 
2.2.3.5 Functional assays at primary human leukocytes 
Assays at human eosinophils and neutrophils cells were performed by Petra Luschnig 
from the group of Prof. Dr. Akos Heinemann, Department of Experimental and Clinical 
Pharmacology, Medical University of Graz, Austria. 
 
Eosinophil and neutrophil Calcium flux assay 
Calcium flux assays at primary human eosinophils and neutrophils were performed as 
described previously (Heinemann et al., 2003). 
 
2.2.4 Computational modeling  
Computational modeling analyses were performed by Angel Gonzalez from the group 
of Prof. Dr. Leonardo Pardo, Laboratory of Computational Medicine, Universitat 
Autònoma de Barcelona, Barcelona, Spain.  
 
Computational modeling of complexes between OXE-R antagonists and the OXE 
receptor 
A homology model of the OXE-R was created with Modeller v9.5 (Martí-Renom et al., 
2000) based on the crystal structure of the chemokine CXCR4 receptor (PDB code 
3ODU). The relative orientation of the side chains at the extracellular side 2 is modified 
by TM 2 of CXCR4 (Wu et al., 2010), making a tighter helical turn at the TxP2.58 
motif (NxP1482.58 in the OXE-R). For compiling Gü 1157, Gü 1158 and compound 
11852816, the general Amber force field (GAFF) with HF/6-31G*-derived RESP 
atomic charges was used, and the Sander module of AMBER 10 (Case et al., 2008) was 
used to energy-minimize the ligand-receptor complexes.  
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Virtual screening of commercially available compounds with predicted 
antagonistic activity on the OXE-R 
Molecules presenting the characteristic properties of Gü 1157 and Gü 1158, which are a 
molecular weight in the range of 350-450 and the number of hydrogen bond donors and 
acceptors ≤ 3, were filtered from the ZINC data base of commercially available 
compounds (URL http://zinc.docking.org 4; Irwin et al., 2005). PyPx and AutoDock 
Vina virtual screening tools 5 were used to dock the resulting hits into the binding 
pocket of the OXE-R, which was ascertained within a 20Å radius sphere around the 
centroid of Gü 1157 and Gü 1158 in their complex with the OXE-R model, as depicted 
in fig. 12. For selection of the best 100 compounds, the Autodock scoring function was 
used.  
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3.1 OXE-R antagonist screening in calcium mobilization assays 
3.1.1 Determination of calcium mobilization capabilities of the OXE-R in 
HEK293 cells 
For OXE-R antagonist screening in calcium mobilization assays, a HEK293 cell line 
stably expressing the OXE-R R527 as well as the promiscuous Gα subunit G16, referred 
to as HEK-OXE-R-G16, was used, which was provided by the group of Prof. Dr. Evi 
Kostenis. In an initial assay, the OXE potency in the HEK-OXE-R-G16 cell line was 
determined using calcium mobilization assays (section 2.3.1). An OXE concentration 
effect curve was established, yielding a pEC50 for OXE of 7.75 ± 0.04 (fig. 9a). Howev-
er, this OXE potency determined for the HEK-OXE-R-G16 cell line used by our group 
was 10-fold increased compared to the OXE potency obtained by Jones et al. (2003) for 
their stable HEK-OXE-R-G16 cell line.  
Due to the findings of Hosoi et al. (2002) that the OXE-R TG1019 is able to mobilize 
calcium via Gi in CHO cells, it was examined if calcium mobilization via Gi could also 
be detected for the OXE-R version R527 in HEK293 cells. Therefore, HEK293 cells 
were transiently transfected with either the OXE-R alone or in combination with the 
OXE-R and the promiscuous Gα subunit of G16 (cDNAs used are according to section 
2.1.8). 48 h after transfection, cells were analysed for OXE triggered calcium mobi-
lization. Calcium flux could be detected in HEK293 cells co-transfected with the OXE-
R and Gα16, but not in cells lacking the promiscuous Gα protein (fig. 9b).  
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Figure 9: Effects of OXE on calcium mobilization in HEK293 cells expressing the OXE-R. 
(a) Concentration effect curve for OXE in HEK293 cells stably expressing OXE-R and Gα16, 
resulting from calcium mobilization. The calcium response was normalized to the maximal 
calcium response achieved with 300 nM OXE. The pEC50 for OXE was 7.75 ± 0.04. (b) 
HEK293 cells transiently transfected with pcDNA3.1-OXE-R (R527) alone do not mobilize 
calcium after treatment with 5-oxo-ETE. However, HEK293 cells transiently co-transfected 
with pcDNA3.1-OXE-R and pcDNA3.1-Gα16 show a calcium release. Calcium mobilization 
was measured as increase in fluorescence, expressed as arbitrary units. Shown are representative 
data (+ SEM) of at least three independent experiments performed in triplicates. (c) OXE-
induced calcium mobilization in HEK-OXE-R-G16 cells is not blunted after pre-treatment with 
50 ng/ml pertussis toxin (PTX) for 18 h. Data are shown as mean values (± SEM) of three 
independent experiments, each performed in triplicates. 
 
Obviously, it is necessary to funnel the OXE-R R527 to the Gq pathway by a promiscu-
ous G protein to obtain detectable amounts of calcium in HEK293 cells. In order to ex-
amine if OXE-R G16 signaling in HEK293 cells is affected by endogenously expressed 
Gi proteins, HEK-OXE-R-G16 cells were exposed to OXE after pre-treatment with PTX 
(50 ng/ml, 18 h). As depicted in fig. 9c, G16-mediated calcium flux was not affected 
when Gi proteins were inactivated by PTX. Hence, it was concluded that Gi signaling 
does not contribute to or affect G16 signaling of the OXE-R in HEK-OXE-R-G16 cells. 
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3.1.2 OXE-R antagonist screening of a compound library in calcium mobilization 
assays 
About a hundred compounds from the in house compound library of the group of Prof. 
Evi Kostenis were tested on HEK-OXE-R-G16 cells for their ability to inhibit OXE-
induced intracellular calcium increase. The antagonist screening was based on two 
measurements: In a first measurement, the compounds were assayed for OXE-R 
agonism, in order to exclude a false-positive effect in antagonism testing. To this end, 
10 µM of each compound was added to the cells, and the cell response was recorded 
immediately after compound addition. After compound incubation for 30 min, 
antagonistic activity was analysed by addition of 500 nM OXE, the OXE EC80 value 
determined from OXE concentration effect curves established in section 3.1.1, fig. 9a. 
No compounds were found to exhibit inhibitory activity at OXE triggered calcium 
mobilization of HEK-OXE-R-G16 cells, until a subset of compounds, which was 
obtained from Prof. Dr. Gütschow, Institute of Pharmaceutical Chemistry, University of 
Bonn, was analysed. Two compounds were found to exhibit inhibitory effects at OXE-
induced calcium release (fig. 10b), without displaying agonistic effects on the cells (fig. 
10a): Gü 1157 (fig. 10c) and Gü 1158 (fig. 10d), two structurally related benzothiazin 
derivatives.  
 
Figure 10: Screening for compounds with antagonistic activity on the OXE receptor in 
calcium mobilization assays. (a) No calcium mobilization could be detected after addition of 
10 μM compound to HEK-OXE-R-G16 cells. (b) After incubation for 30 min, cells were 
challenged with 500 nM OXE. Gü 1157 (c) and Gü 1158 (d) exhibited antagonistic activity on 
calcium response of the OXE-R. Shown are representative data (+ SEM) of at least three 
independent experiments in triplicates. Structures of the tested compounds are depicted in 
section 8.  
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Both compounds were chosen to be further characterized for antagonistic effects on the   
OXE-R. 
3.1.3 Elucidation of unspecific cellular effects of Gü 1157 and Gü 1158  
Before Gü 1157 and Gü 1158 were further explored for OXE-R antagonism in more 
detail, they were subjected to an additional test using the DMR technology in order to 
analyse unspecific, compound-triggered cellular effects. Briefly, in DMR assays the cell 
response to GPCR activation is measured as intracellular change of molecules in real 
time. Polarized light is passed through the bottom of cells located on a biosensor, and 
the reflected light is measured. After GPCR activation, resulting in G-protein signaling, 
intracellular reactions take place, and intracellular mass changes are detected as a shift 
in wavelength of the reflected light. Due to the ability of the DMR technology to detect 
whole cell responses, the DMR assay is a well suited tool for the analysis of unspecific 
cell reactions upon compound treatment, which might lead to false-positive results in 
further experiments.  
In DMR assays, Gü 1157 and Gü 1158 were analysed on HEK293 cells stably 
expressing the Gi coupled GPCR chemoattractant receptor-homologous molecule 
expressed on Th2 cells (CRTH2). Prior to the assay, HEK-CRTH2 cells were seeded 
into fibronectin-coated biosensor microplates according to the DMR assay protocol in 
section 2.3.4, and were grown for 24 hours till the assay. For analysis of unspecific 
compound effects, HEK293-CRTH2 cells were challenged with 3, 10 and 30 µM Gü 
1157 or Gü 1158, respectively, or buffer as control. Meanwhile, the DMR response was 
recorded. During compound incubation for 30 minutes, negative DMR responses of 
CRTH2-HEK cells could be observed at compound concentrations of 30 µM of Gü 
1157 (fig. 11a) and 10 and 30 µM of Gü 1158 (fig. 11b). These negative DMR 
responses probably depict cell stimulation due to Gü 1157 and Gü 1158. In order to 
analyse if cell responsiveness to the CRTH2 agonist PGD2 would be affected due to 
cellular stimulation, cells were challenged with 30 nM PGD2. The recorded DMR 
traces revealed that the PGD2 mediated cell response was not affected by Gü 1157 (fig. 
11c) and Gü 1158 (11d), respectively. Gü 1157 and Gü 1158 also triggered negative 
DMR responses when tested on native HEK293 cells (data not shown), proving that 
cellular responses upon compound treatment were not related to interaction with 
CRTH2.  
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These findings revealed that Gü 1157 and Gü 1158 induced unspecific negative DMR 
responses in HEK293 cells, but did not alter cell responsiveness to agonist. In 
conclusion, both compounds were chosen to be further characterized for antagonistic 
activity on the OXE-R. 
 
Figure 11: Analysis of potential unspecific cellular effects of Gü 1157 and Gü 1158 on the 
DMR response of HEK-CRTH2 cells to PGD2. Stable HEK-CRTH2 cells were incubated 
with increasing concentrations of Gü 1157 (a) and Gü 1158 (b) and responded with negative 
DMRs to concentrations of 30 μM Gü 1157 and 10 and 30 μM Gü 1158, respectively. The 
HEK-CRTH2 cell response to 30 nM PGD2 is not affected by Gü 1157 (c) and Gü 1158 (d), 
respectively. Shown are representative data (mean + SEM) of at least three independent 
experiments, each performed in triplicates.  
 
3.1.4 Computational modeling of compounds with antagonistic activity on the 
OXE-R devoid of unspecific cellular effects 
 
Based on the structures of Gü 1157 and Gü 1158, a virtual screening using 
computational modelling was performed in order to detect an OXE-R antagonist that 
might be devoid of unspecific cellular effects. The computational modelling was 
performed by Angel Gonzalez from the group of Leonardo Pardo, Laboratory of 
Computational Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 
An OXE-R model was built, as previously described in section 2.3.6, using the crystal 
structure of the chemokine receptor CXCR4 as template, and the OXE-R was analysed 
for structural features interacting with molecule structures of Gü 1157 and Gü 1158. 
In the CXCR4-based OXE-R model, charged amino acids within the TM helices 
(R150
2.60
, R176
3.36
 and E260
5.46
) were found to point towards the binding site crevice, 
and in the middle of the transmembrane helices (TM) bundle, the bulky and very polar 
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group of R176
3.36
 is interacting with E260
5.46
 in TM5 and S311
6.51
. It was presumed that 
the protonated amine group of Gü 1157 and Gü 1158 forms an ionic interaction with 
E260
5.46
,
 
and (fig. 12a for Gü 1157 and fig. 12b for Gü 1158), that the aromatic moiety 
of the compounds forms hydrogen bond interactions between their carbonyl groups and 
R176
3.36
 and R150
2.60
, respectively. Additionally, aromatic-aromatic interactions with 
F337
7.35
and edge-to-face interaction between the terminal phenyl ring of the ligands and 
W158 in ECL1 were presumed. 
 
 
 
Figure 12: Computational models of the complex between Gü 1157 (a) and Gü 1158 (b), 
respectively, and the OXE receptor. The color code of the helices is: TM 2 (yellow), TM 3 
(light red), 5 (green), 6 (blue), and 7 (pink). 
 
 
Due to these findings, the ZINC database 4 (Irwin and Shoichet, 2005) was screened for 
commercially available compounds possessing structural features required for 
interaction with the OXE-R, as defined by the computational models. The best 100 
compounds were chosen and docked into the OXE-R model (fig. 13), and the best 10 
compounds were selected and ordered. 
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Figure 13: 100 compounds selected from ZINC database screening of commercially 
available compounds were docked into the OXE-R model. 
 
Eight compounds were obtained and tested in calcium mobilization assays for 
antagonistic activity on the OXE-R. None of the compounds did trigger calcium flux of 
HEK-OXE-R-G16 cells when added to the cells (fig. 14a), but only one compound, 
11852816, exhibited significant inhibitory effects on OXE mediated calcium 
mobilization, as compared to 10 μM Gü 1157 and Gü 1158, respectively (fig. 14b).  
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Figure 14: Analysis of antagonistic activity of virtual screening hits derived from the 
ZINC database in calcium mobilization assays and analysis of unspecific cellular effects of 
compound 11852816 in DMR assays. After addition of 10 μM 11852816 to HEK-OXE-R-G16 
cells, no calcium mobilization could be detected (a). After pre-incubation with the indicated 
ligands for 30 min, cells were challenged with 500 nM OXE. Compound 11852816 displayed 
antagonistic activity at the calcium response of the OXE-R as compared to 10 μM Gü1157 and 
Gü1158, respectively (b). HEK-CRTH2 cells do not respond with a DMR response to 
increasing concentrations of 11852816 (c). After compound pre-incubation for 30 minutes, the 
30 nM PGD2 DMR response is not affected (d). Shown are representative data (+ SEM) of at 
least three independent experiments, each performed in triplicates. Structures of the tested 
compounds are depicted in section 8. 
 
Following these results, compound 11852816 was also tested for unspecific effects on 
CRTH2-HEK cells in DMR assays, in order to analyse if the computational modeling 
approach indeed yielded an OXE-R antagonist devoid of unwanted effects. It could be 
shown that compound 11852816 neither triggered unspecific DMR responses in HEK-
CRTH2 cells (fig. 14c), nor did the substance affect the PGD2 mediated CRTH2 
response (fig. 14d).  
In contrast to Gü 1157 and Gü 1158, compound 11852816, which is a benzobisthiazole 
derivative (fig. 15a), lacks the protonated amine group, but R176
3.36
 and E260
5.46 
also
 
form ionic interaction R176
3.36
 and E260
5.46 
in the ligand-unbound receptor (fig. 15b). 
Compound 11852816 mainly interacts with the OXE-R by hydrogen bonds between 
R176
3.36
 and R150
2.60
 and by aromatic-aromatic interactions with F337
7.35
. The two 
terminal phenyl rings of compound 11852816 occupy the two different aromatic 
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pockets of the OXE-R, formed by either W158 in ECL1 and Tyr151
2.63
 Tyr152
2.64
 in 
TM2, thus representing another significant structural feature of this compound.  
 
Figure 15: Structure of compound 11852816 and computational model of the complex 
between compound 11852816 and the OXE-R. (a) Molecule structure of compound 
11852816. (b) Computational model of the complex between compound 11852816 and the 
OXE-R. The color code of the helices is: TM 2 (yellow), TM 3 (light red), 5 (green), 6 (blue), 
and 7 (pink). 
 
In order to analyse if particular structural features of compound 11852816 are 
responsible for antagonistic activity on the OXE-R, molecular fragments of 11852816 
were synthesized by Philipp Ottersbach from the group of Prof. Dr. Gütschow, Institute 
of Pharmaceutical Chemistry, University of Bonn. In addition, compound 11852816 
was also re-synthesized. 
3.1.5 OXE-R   antagonist   screening   of   compounds   derived   from   fragment 
based synthesis of compound 11852816 
Eight compounds were derived from the fragment based synthesis of compounds 
structurally related to compound 11852816. The new synthesized compounds and the 
re-synthesized compound 11852816, hereafter named Gü 1654, were tested for 
antagonistic activity on the OXE-R in calcium mobilization assays. None of the newly 
synthesized compounds displayed antagonistic effects on the OXE-R (fig. 16b), thus 
proving that all structural features of the molecule described in section 3.1.4 are 
required for biological activity of compound 11852816. However, Gü 1654 was shown 
to exhibit equal antagonistic activity on the OXE mediated calcium response as the 
original compound 11852816. 
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Figure 16: Screening of new synthesized compounds based on the structure of compound 
11852816 for antagonistic activity on the OXE-R. (a) After addition of 10 μM per compound 
to HEK-OXE-R-G16 cells, no calcium flux was obtained. (b) After compound pre-incubation for 
30 min, cells were challenged with 500 nM OXE. Except for compound 11852816 and its re-
synthetized analogue Gü 1654, no other compound displayed antagonistic activity at the OXE-R 
calcium response. Shown are representative data (mean + SEM) of at least three independent 
experiments. Structures of the tested compounds are depicted in section 8. 
 
Data derived from calcium mobilization assays proved Gü 1654 to be a putative OXE-R 
antagonist devoid of unspecific cellular effects. Together with Gü 1157 and Gü 1158, 
Gü 1654 was chosen to be further examined for antagonism on the OXE-R in calcium 
mobilization assays. 
3.1.6 Characterization of the nature of antagonism of Gü 1157, Gü 1158 and Gü 
1654 in calcium mobilization assays 
OXE concentration effect curves were elaborated after cell pre-incubation with 3, 10 
and 30 µM Gü 1157, Gü 1158, and Gü 1654, respectively, or buffer as control. A 
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concentration-dependent decrease in the maximal OXE response was produced by all 
compounds, indicating insurmountable antagonism of Gü 1157 (fig. 17a), Gü 1158 (fig. 
17b) and Gü 1654 (fig. 17c) at the OXE-R.  
 
Figure 17: Insurmountable antagonism of Gü 1157, Gü 1158 and Gü 1654 on the OXE-R 
calcium response of HEK-OXE-R-G16 cells. HEK-OXE-R-G16 cells pre-treated with the 
indicated concentrations of Gü 1157 (a), Gü 1158 (b) and Gü 1654 (c), respectively, for 30 min 
were challenged with increasing concentrations of OXE. Increasing compound concentrations 
depressed maximal OXE efficacy. All data are means ± SEM of at least three independent 
experiments, each performed in triplicates. 
 
Together, Gü 1157, Gü 1158 and Gü 1654 were found to exhibit inhibitory activity on 
the G16 pathway of the OXE-R, displaying insurmountable antagonism when tested in 
increasing concentrations. The next aim of this work was to test these compounds for 
their ability to inhibit OXE-R signaling on the native Gi pathway of the receptor. 
3.1.7 Discussion 
From an OXE-R antagonist screening, two compounds were obtained with antagonistic 
activity on the OXE-R, Gü 1157 and Gü 1158. Because both compounds were found to 
exhibit unspecific cellular effects, a virtual screening was performed in order to detect 
an “improved” compound with antagonistic activity on the OXE-R but devoid of 
unwanted cellular effects. The virtual screening indeed yielded a compound only 
possessing the wanted properties: Gü 1654. Synthesized molecule fragments of Gü 
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1654 did not exhibit antagonistic activity on the OXE-R, proving that all structural 
features of Gü 1654 were necessary to maintain antagonistic activity.  
The nature of antagonism of Gü 1157, Gü 1158 and Gü 1654 was investigated. OXE 
concentration effect curves were established after cell pre-incubation with increasing 
compound concentrations, and a decrease in the maximal OXE response was observed, 
implying insurmountable antagonism. Insurmountable antagonism after compound pre-
incubation can either result from competitive antagonism by a slow-dissociating 
orthosteric antagonist or from non-competitive antagonism by an allosteric antagonist.  
An orthosteric antagonist binds to the same receptor binding site as the receptor agonist, 
therefore both ligands compete for binding to the same site. When antagonist and 
agonist are added at the same time, the competitive antagonist produces a rightward 
shift of the agonist concentration effect curves which increases with increasing 
antagonist concentrations. In the present work, the OXE-R was pre-incubated and thus 
pre-equilibrated with antagonist before agonist was added. Assuming that the binding of 
Gü 1157, Gü 1158 and Gü 1654 to the receptor is slowly reversible, antagonist 
liberation from the OXE-R by agonist would take so long that the agonist cannot 
interact with the receptor at the time when the agonist response is measured. Thus, the 
maximal agonist response cannot be attained and a decrease of the maximal agonist 
response is produced (Kenakin et al., 2006; Vauquelin and Szczuka, 2007).  
An allosteric antagonist binds to a site distinct from the orthosteric receptor binding site. 
Antagonist binding to the receptor cannot be reversed by the agonist, so that the agonist 
response is affected and decreased for the maximal response. 
The molecular mechanism of antagonist-receptor interaction underlying insurmountable 
antagonism can be analysed by radioligand binding assays (Mathiesen et al., 2006), but 
as radiolabelled OXE is not commercially available, such experiments were not 
performed. In conclusion, Gü 1157, Gü 1158 and Gü 1654 were found to display 
insurmountable antagonism at G16 signaling of the OXE-R. The next aim of this work 
was to analyse the compounds for antagonistic activity on the native Gi pathway of the 
OXE-R.  
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3.2 Investigations of antagonistic activity of Gü 1157, Gü 1158 and 
Gü 1654 on the OXE-R Gi pathway in cAMP accumulation 
assays 
 
Three compounds were found to exhibit insurmountable antagonism on the G16 pathway 
of the OXE-R: Gü 1157, Gü 1158 and Gü 1654. In order to analyse the antagonistic 
activity of these compounds on the native Gi pathway of the OXE-R, the compounds 
were also tested for inhibitory effects on OXE mediated inhibition of forskolin-
stimulated adenylyl cyclase activity in cAMP accumulation assays. In this assay, cAMP 
production is quantified by time-resolved fluorescence resonance energy transfer 
technology, based on a competition immunoassay as described in section 2.3.2. 
Measurement of Gi signaling of over-expressed OXE-R via cAMP accumulation assays 
has already been described in the literature: Jones et al. (2003) reported OXE mediated 
inhibition of forskolin-stimulated adenylyl cyclase for their stable HEK-OXE-R-G16 cell 
line in a radiochemical cAMP accumulation assay, gaining an EC50 value for OXE of 
0.33 ± 0.1 nM. Hosoi et al. (2002) measured OXE dose-dependent inhibition of cAMP 
formation in CHO cells transiently transfected with the OXE-R in a cAMP enzyme 
immunoassay, where an EC50 value of 33 ± 19 nM was detected. As in this work the 
same cell system was used as by Jones et al., a similar OXE potency for inhibition of 
forskolin-stimulated adenylyl cyclase in cAMP accumulation assays was expected to be 
obtained. 
Until now, antagonistic activity on the Gi pathway of the OXE receptor has only been 
reported for the 12-LO metabolites 5-oxo-12-HETE and 8-trans-5-oxo-12-HETE 
(Powell et al., 1999), as examined by Gi calcium flux assays with in neutrophils 
endogenously expressed OXE-R. As these OXE metabolites are endogenously formed 
substances, Gü 1157, Gü 1158 and Gü 1654, respectively, would be the first small 
molecule compounds to be found exhibiting antagonistic activity on the Gi pathway of 
the OXE-R.    
 
3.2.1 Determination of Gi signaling of the OXE-R by cAMP accumulation assays 
Forskolin was tested in different concentrations in cAMP accumulation assays for its 
adenylyl cyclase stimulation capabilities in HEK-OXE-R-G16 cells. Adenylyl cyclase 
stimulation with 0.5 µM forskolin turned out to create an optimal assay window (data 
50   3 Results 
not shown), so that for adenylyl cyclase stimulation in the following cAMP 
accumulation experiments a forskolin concentration of 0.5 µM was applied. 
An OXE dose effect curve was established in cAMP accumulation assays using HEK-
OXE-R-G16 cells. Forskolin-induced cAMP formation was concentration-dependently 
inhibited by increasing concentrations of OXE with a pEC50 value of 6.67 ± 0.1 (fig. 
16), which is a 648 fold decreased OXE potency compared to the data published by 
Jones et al. (2003) using the same cell system. Treatment of HEK-OXE-R-G16 cells 
with 50 ng/ml PTX for 18 hours completely abolished the OXE mediated inhibition of 
forskolin-stimulated cAMP production, confirming that adenylyl cyclase inhibition is 
Gi-mediated (fig. 18).  
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
   - PTX
  + PTX
OXE (log M)
c
A
M
P
(%
 o
f 
0
.5
 µ
M
 F
S
K
)
 
Figure 18: OXE mediates inhibition of forskolin stimulated adenylyl cyclase in HEK-
OXE-R-G16 cells. cAMP production by forskolin-stimulated adenylyl cyclase was 
concentration dependently inhibited by increasing concentrations of OXE and is Gi mediated as 
proven by the use of PTX (50 ng/ml for 18 h). cAMP values are calculated as percent inhibition 
of 0.5 µM forskolin. Data are mean ± SEM of at least three independent experiments, each 
performed in triplicates. 
 
3.2.2 Analysis of antagonistic activity of Gü 1157, Gü 1158 and Gü 1654 on the Gi 
pathway of the OXE-R  
Before Gü 1157, Gü 1158 and Gü 1654 were tested for antagonistic activity exclusively 
on the Gi pathway of the OXE-R, the compounds were analysed for stimulating and 
inhibitory effects on the adenylyl cyclase in HEK-OXE-R-G16 cells. As shown in fig. 
18a, Gü 1157, Gü 1158 and Gü 1654 did neither inhibit forskolin-stimulated adenylyl 
cyclase, nor did the compounds act as adenylyl cyclase stimulants.  
For analysis of antagonistic activity on the Gi pathway of the OXE receptor, OXE dose 
effect curves were established after pre-incubation with 3 µM, 10 µM and 30 µM of 
each compound. Surprisingly, no antagonistic effect on OXE mediated inhibition of 
forskolin- stimulated adenylyl cyclase was detected for all three compounds (fig. 18b, c, 
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d), indicating that Gü 1157, Gü 1158 and Gü 1654 do not act as antagonists on the Gi 
pathway. 
 
Figure 18: Analysis of Gü 1157, Gü 1158 and Gü 1654 for inhibitory effects on OXE 
mediated inhibition of cAMP production in HEK-OXE-R-G16 cells. Adenylyl cyclase was 
neither stimulated nor inhibited by individual effects of 30 µM Gü 1157, Gü 1158 and Gü 1654, 
respectively (a). None of the compounds displayed antagonistic activity on OXE mediated 
inhibition of adenylyl cyclase stimulated with 0.5 µM forskolin (Gü 1157: b, Gü 1158: c, Gü 
1654: d). Data shown are mean values and SEM of three independent experiments, each 
performed in triplicates. 
 
Because Gü 1157, Gü 1158 and Gü 1654 exhibited antagonistic activity on the G16 but 
not on the Gi pathway of the OXE-R, data suggest that these compounds are able to 
discriminate between G protein subfamilies and thus may act as “biased antagonists”. 
To confirm this hypothesis, Gü 1157, Gü 1158 and Gü 1654 needed to be analyzed for 
inhibitory effects on G16 and Gi signaling in a different assay.   
 
3.2.3 Discussion 
In the present chapter, Gü 1157, Gü 1158 and Gü 1654 were tested for antagonistic 
activity on the native Gi pathway of the OXE-R in cAMP accumulation assays using the 
same cell line as previously used for calcium mobilization assays. Remarkably, none of 
the compounds exhibited inhibitory effects on the OXE mediated inhibition of 
forskolin-stimulated adenylyl cyclase. Data indicates that Gü 1157, Gü 1158 and Gü 
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1654 are able to discriminate between G16 and Gi signaling of the OXE-R, exhibiting a 
so-called “biased antagonism” for different G protein subfamilies. Most GPCR 
antagonists inhibit all G protein subtypes a receptor couples to. Until now, the ability of 
antagonists to discriminate between GPCR signaling via different G proteins has only 
been reported by two groups: (i) A sequential binding process of the orthosteric NK2R 
agonist neurokinin A (NKA) to the tachykinin NK2 receptor (NK2R) was found to 
stabilize the receptor in two active conformations (Holst et al., 2001), each of which 
were shown to specifically activate the Gq or the Gs pathway. Maillet et al. (2007) 
discovered the compound LPI805 to inhibit Gs signaling of the NK2R, whereas at the 
same time Gq signaling of the NK2R was not inhibited, rather, Gq mediated calcium 
responses were found to be enhanced in the presence of LPI805. LPI805 was found to 
act as allosteric antagonist. (ii) Dowal et al. (2011) determined biased antagonism at G 
protein signaling for a small molecule exhibiting antagonistic activity at the thrombin 
receptor PAR1, a GPCR endogenously expressed on platelets, which is known to signal 
via Gq, G12/13 and Gi protein α subunits (Swift et al., 2006). Dowal et al. found the 
cyclopentaquinoline-derivative JF5 to act as PAR1 antagonist, and further 
investigations on PAR1 signaling in platelets revealed that JF5 specifically inhibits Gq 
but not G12 mediated signaling of the PAR1 receptor. Although the molecular 
mechanism of this biased antagonism remained unknown, Dowal et al. showed that JF5 
is a non-orthosteric antagonist, and mutagenesis studies indicated that antagonistic 
activity of JF5 is conferred through the intracellular eighth helix of the PAR1 receptor, 
which functions in coupling to Gα subunits.  
Possibly, Gü 1157, Gü 1158 and Gü 1654 could also act as intracellular allosteric 
antagonists on the OXE-R leading to an altered receptor conformation resulting in a 
modified G protein binding site which would explain the ability of the antagonistic 
compounds to discriminate between G16 and Gi signaling of the OXE-R. Since the aim 
of this work was to investigate the antagonistic activity on different signaling pathways 
of the OXE receptor and its impact on OXE mediated effects in primary cells, no 
studies for the analysis of the molecular mechanism of the presumed “biased 
antagonism” of Gü 1157, Gü 1158 and Gü 1654 were realized. Instead, it was decided 
to analyse the three compounds once more in a different assay system for their ability to 
discriminate between inhibition of Gi and G16 to see if these experiments would 
conform the hypothesis of biased antagonism.  
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Additionally, the receptor specificity of G16 inhibition remained to be analysed, 
meaning that it had to be tested whether there is only inhibition of OXE-R mediated G16 
coupling and not a GPCR independent inhibition of G16 signaling. Since specific G 
protein inhibitors exist, as e.g. YM-254890, which acts as inhibitor of the GDP/GTP 
exchange reaction of the alpha subunit of Gq proteins (Nishimura et al., 2010), a 
universal inhibition of G16 by Gü 1157, Gü 1158 and Gü 1654 needs to be considered as 
a possible reason for the antagonistic effect on G16, but not on Gi signaling. Thus, after 
confirmation of the putative biased antagonism of Gü 1157, Gü 1158 and Gü 1654 at 
OXE-R signaling, appropriate experiments should be performed to address the 
possibility that these compounds act as universal G16 inhibitors. 
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3.3 Investigations of the biased antagonism of Gü 1157, Gü 1158 and 
Gü 1654 on the OXE-R using DMR assays 
 
In previous cAMP accumulation assays, Gü 1157, Gü 1158 and Gü 1654 did not show 
inhibitory activity on the Gi pathway of the OXE-R. The results from cAMP assays 
were in contrast to the results derived from calcium assays, where the compounds had 
been discovered for their antagonistic activity on the G16 pathway of the OXE-R. These 
findings implicated that Gü 1157, Gü 1158 and Gü 1654 were able to discriminate 
between different G protein subfamilies. To confirm by another assay that these 
compounds are really inactive on the Gi pathway but not on the G16 pathway of the 
OXE-R, dynamic mass redistribution (DMR) assays were performed.  
The DMR technology has been evaluated as an approved method to analyse GPCR 
signaling of all four G protein classes (Schröder et al., 2010). Distinct from the 
previously used second messenger assays, the DMR method captures the downstream 
cellular effects of all G proteins, resulting in a whole cell response. Thus, this method 
provided a valuable tool to prove the hypothesis of the “biased antagonism” from a 
holistic point of view.  
 
If a GPCR couples to G proteins of different G protein classes at the same time, in the 
DMR assay a complex DMR signal will be obtained consisting of mixed signatures 
from all different G protein pathways. To dissect and visualize a single pathway 
component of a complex DMR signal, toxins or pharmacological pathway inhibitors can 
be used (Schröder et al., 2010). For example, the Gi pathway can be abrogated with 
PTX, Gs signaling can be masked by CTX and Gq signaling can be abolished by the Gq 
inhibitor YM-254890 (Schröder et al., 2010). In HEK-OXE-R-G16 cells, the OXE-R 
couples to co-expressed promiscuous Gα16 and to endogenously expressed Gi proteins. 
Thus, DMR recordings of OXE-R signaling in these cells would disclose a mixed Gi-
G16 DMR signal.  
To confirm antagonism of Gü 1157, Gü 1158 and Gü 1654, respectively, on the G16 
pathway of the OXE-R in DMR assays, HEK-OXE-R-G16 would have to be treated with 
PTX to deactivate Gi proteins and accordingly obtain an isolated OXE-R G16 response.  
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To analyse the antagonistic activity of Gü 1157, Gü 1158 and Gü 1654 on the isolated 
Gi response of the OXE-R in HEK-OXE-R-G16 cells, the G16 pathway would need to be 
blocked, but currently no G16 inhibitor exists. Although G16 belongs to the Gq/11 family 
of G proteins, and YM-254890 is known to be a potent and selective inhibitor for Gq/11 
proteins, this compound has lately been reported not to exhibit inhibitory activity at G16 
proteins (Nishimura et al., 2010). Thus, analysis of Gü 1157, Gü 1158 and Gü 1654 on 
the Gi pathway of the OXE-R in DMR assays had to be performed in HEK293 cells 
transiently transfected with the OXE-R in order to detect isolated Gi signaling of the 
OXE-R. 
 
3.3.1 Visualization of isolated OXE-R G16 signaling in DMR assays 
HEK-OXE-R-G16 cells were analyzed for OXE-R signaling via G16 in DMR assays. 
Therefore, HEK-OXE-R-G16 cells were challenged with increasing concentrations of 
OXE in the presence and absence of PTX, and the cell response was recorded and 
visualized as wavelength shift (fig. 20a,b). Both the cumulative Gi-G16 and the isolated 
G16 response displayed robust and concentration-dependent signals to the agonist. For 
comparison, HEK293 cells were challenged with OXE, where no DMR response was 
observed which proved the OXE-R specificity of the OXE mediated cell response (fig. 
20c). 
To quantify both the mixed Gi-G16 DMR and the isolated G16 responses, the maximum 
values between 400 and 1800 seconds of the DMR response were selected from each 
OXE concentration, and OXE concentration effect curves were established (fig. 20d). 
Data revealed, that when Gi signaling was abolished by PTX, OXE-R signaling via the 
G16 pathway was reinforced (fig. 20d,e).  
Remarkably, the potency obtained from OXE-R G16 signaling in DMR assays (pEC50 
5.39 ± 0.09) was about 225 fold decreased compared to the potency obtained from 
OXE-R G16 signaling in calcium mobilization assays (pEC50 7.75 ± 0.04; section 3.1.2).  
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Figure 20: Visualization of OXE triggered Gi-G16 signaling and isolated G16 signaling of 
HEK-OXE-R-G16 cells in DMR assays. DMR responses were obtained from HEK-OXE-R-G16 
cells due to Gi-G16 signaling (a) and G16 signaling after PTX treatment (50 ng/ml for 18 h) (b), 
but not from native HEK293 cells (c). Concentration effect curves in (d) were established for 
OXE from the maximal DMR values between 400-1800 s from (a) and (b), and mean data (+ 
SEM) from three independent experiments were normalized for the maximum response of 30 
µM OXE in PTX-treated cells (e). The pEC50 value of OXE is 5.39 ± 0.09 for G16 signaling, and            
5.05 ± 0.08 for complex Gi-G16 signaling. 
 
3.3.2 Investigations of the antagonism of Gü 1157, Gü 1158 and Gü 1654 on the 
G16 pathway of the OXE-R in DMR assays 
Antagonism analyses were performed on the isolated G16 response of HEK-OXE-R-G16 
cells. PTX-treated cells were pre-incubated for 30 minutes with 30 µM Gü 1157, Gü 
1158 and Gü 1654, respectively, or buffer as control, and were challenged with 
increasing concentrations of OXE. The OXE mediated DMR response was not affected 
by Gü 1157 and Gü 1158. However, OXE concentration effect curves displayed a bell-
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shape here. In contrast, Gü 1654 exhibited consistent and potent inhibition of the G16 
cell response to OXE (fig. 21).  
 
Figure 21: Analysis of antagonistic effects of Gü 1157, Gü 1158 and Gü 1654 on the G16 
pathway of the OXE-R in DMR assays. PTX-treated HEK-OXE-R-G16 cells (50 ng/ml, 18 h) 
were challenged with increasing concentrations of OXE after pre-incubation with 30 µM of Gü 
1157, Gü 1158 and Gü 1654, respectively, or buffer as control. Only Gü 1654 exhibited 
antagonistic activity on the OXE-R G16 DMR response. (a) Data points are curve-fitted by non-
linear regression. (b) Data points are aligned for visualization of the bell-shaped OXE response 
upon treatment with Gü 1157 and Gü 1158, respectively. Data are mean and SEM of three 
independent experiments, each performed in triplicates. 
 
Thus, the antagonistic effects of Gü 1157 and Gü 1158 on the G16 pathway of the OXE-
R discovered in calcium mobilization assays could not be reproduced in DMR assays.  
Due to these findings, only Gü 1654 was further analysed in DMR assays for 
antagonistic effects on the OXE-R in concentrations of 1, 3, 10 and 30 µM, 
respectively. DMR analysis proved concentration-dependent antagonism of Gü 1654 at 
the OXE mediated cell response (fig. 22), confirming the findings in calcium 
mobilization assays.  
 
Figure 22: Gü 1654 concentration-dependently inhibits the OXE mediated G16 response of 
the OXE-R in DMR assays. After pre-incubation with Gü 1654 in increasing concentations, 
PTX-treated HEK-OXE-R-G16 cells (50 ng/ml, 18 h) were challenged with 3 µM OXE. The G16 
mediated DMR responses were concentration-dependently inhibited by increasing 
concentrations of Gü 1654, and are normalized to the maximum response of 3 µM OXE. Data 
are mean (+ SEM) of three independent experiments, each performed in triplicates. 
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3.3.3 Analysis  of  antagonistic  activity  of  Gü  1654  on   the Gi  pathway  of  the   
OXE-R in DMR assays 
Gü 1654 was analysed for its non-antagonistic effect on the Gi pathway of the OXE-R 
in DMR assays to confirm the hypothesis of “biased antagonism”. Because antagonism 
of Gü 1157 and Gü 1158 on the G16 OXE-R pathway had not been confirmed in DMR 
assays, both compounds were no longer analyzed in DMR assays.    
Signaling of the OXE-R transiently expressed in HEK293 cells was visualized upon 
treatment with OXE in DMR assays yielding an OXE pEC50 value of 6.11 ± 0.21. Since 
the DMR response was completely abolished by PTX pre-treatment (fig. 23), the DMR 
signal was exclusively based on Gi coupling of the OXE-R. The pEC50 determined in 
the DMR assay is in good agreement with the pEC50 of 6.67 ± 0.09 obtained for OXE-R 
Gi signaling in cAMP accumulation assays (section 3.2.2). Pre-incubation with 30 µM 
Gü 1654 did not inhibit or attenuate the OXE-R DMR response. These DMR data 
confirmed the observations made in Gi cAMP accumulation assays: Gü 1654 does not 
inhibit signaling via the Gi pathway of the OXE-R.  
 
Figure 23: Analysis of Gü 1654 for inhibitory activity on Gi signaling of the OXE-R in 
DMR assays. HEK293 cells transiently expressing the OXE-R were challenged with increasing 
concentrations of OXE after pre-incubation with 30 µM Gü 1654, or buffer and PTX (50 ng/ml, 
18 h) or buffer as control, for 30 min. Gü 1654 did not affect the OXE mediated Gi response. 
Data are mean (± SEM) of three independent experiments, each performed in triplicates.  
 
3.3.4 Analysis  of  specific  antagonism  of  Gü  1654  on  the  G16  pathway  of the 
OXE-R 
The possibility that inhibition of the G16 response of the OXE-R may be due to 
universal G16 inhibition rather than specific inhibition of G16 coupling to the OXE-R 
was analysed. For analysis of antagonism on the G16 response of another receptor, the 
CRTH2 receptor stably expressed in HEK293 cells was chosen. Upon stimulation with 
its agonist prostaglandin D2 (PGD2), the CRTH2 receptor couples to Gi (Nagata et al., 
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1999a, Nagata et al., 1999b; Hirai et al., 2001), which has already been analysed by 
Schröder et al. (2010) in DMR assays.  
HEK-CRTH2 cells were transiently transfected with the Gα16 subunit, and cells were 
stimulated with PGD2 in the presence and absence of PTX. As control, PGD2 mediated 
DMR responses of non-transfected HEK-CRTH2 cells were measured simultaneously. 
In the absence of PTX, both the Gα16-transfected and the non-transfected HEK-CRTH2 
cells displayed DMR signals up to 300 pm as cell response to PGD2, whereas in the 
presence of PTX (50 ng/ml, 18 h) only Gα16-transfected HEK-CRTH2 cells displayed 
an immediate DMR response due to G16 signaling (fig. 24c,d), as compared to HEK-
CRTH2 cells without Gα16 (fig. 24a,b).    
 
Figure 24: Signaling of CRTH2 funnelled to the G16 pathway in DMR assays. HEK-CRTH2 
cells transiently expressing Gα16 are funnelled to the G16 pathway after pre-treatment with PTX 
(50 ng/ml for 18 h), resulting in a prompt and concentration dependent DMR response (c,d), in 
contrast to HEK-CRTH2 cells without Gα16 (a,b). Shown are representative data (mean + SEM) 
of at least three independent experiments, each performed in triplicates.  
 
Gü 1654 was tested in 3, 10 and 30 µM for inhibitory effects on the PGD2 mediated 
DMR response of CRTH2 funneled to the G16 pathway. After compound pre-incubation 
for 30 minutes, the PGD2 triggered CRTH2 responses were not affected, as displayed 
by the bar diagram depicting the CRTH2 responses normalized to 10 µM PGD2 (fig. 
25).  
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Figure 25: Gü 1654 does not affect the PGD2 mediated G16 response of HEK-CRTH2 cells 
transiently transfected with Gα16. HEK-CRTH2 cells transiently expressing Gα16 were 
funneled to the G16 pathway by pre-treatment with PTX (50 ng/ml for 18h) and incubated with 
increasing concentrations of Gü 1654 for 30 min. The PGD2 triggered G16 response was not 
affected by Gü 1654, as demonstrated by the CRTH2 G16 response normalized to 10 µM PGD2 
(mean ± SEM) data of at least three independent experiments, each performed in triplicates).   
 
This experiment revealed that Gü 1654 is not a universal G16 inhibitor, but specifically 
inhibits OXE-R G16 signaling.  
In summary, the findings obtained in DMR assays investigating the putative biased 
antagonism of Gü 1157, Gü 1158 and Gü 1654 affirmed this hypothesis for at least Gü 
1654 to act as a biased antagonist, competent to inhibit OXE-R signaling when coupled 
to G16 but not when coupled to Gi. 
 
3.3.5 Discussion 
In DMR assays, Gü 1157, Gü 1158 and Gü 1654, respectively, were investigated for the 
proposed “biased antagonism” on the Gi and the G16 signaling pathway of the OXE-R.  
Isolated G16 signaling of the OXE-R was measured in DMR assays after PTX treatment 
of HEK-OXE-R-G16 cells, and Gi signaling of the OXE-R could be detected by transient 
expression of the OXE-R in HEK cells. During the initial DMR experiments for 
visualizing the distinct OXE-R pathways in HEK-OXE-R-G16 cells, two striking 
observations were made: (i) OXE efficacy obtained for G16 signaling of the OXE-R 
achieved by PTX treatment was higher than OXE efficacy derived from mixed Gi-G16 
signaling of the OXE-R (fig. 20d,e), indicating, that when Gi proteins are inactivated by 
PTX, the OXE-R signals were reinforced via the G16 pathway. In contrast to this 
finding, only a small DMR response was detectable when CRTH2 was funneled to the 
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61 
G16 pathway by transient G16 expression and the use of PTX (fig.22). Apparently, the 
OXE-R has a high efficiency for coupling to Gα16 subunits.     
(ii) Comparison of concentration effect curves of OXE obtained from OXE-R G16 
signaling in DMR assays and in G16 second messenger calcium assays revealed that 
OXE potency in holistic G16 DMR assays was 225 fold decreased compared to that in 
second messenger G16 assays (fig. 26a). However, OXE potency for OXE-R Gi 
mediated DMR responses is quite similar to the OXE potency for Gi mediated inhibition 
of cAMP production (fig. 26b).  
Figure 26: Comparison of concentration effect curves of OXE from OXE-R DMR assays 
(red signatures) or second messenger assays (black signatures) for G16 (a) and Gi (b) 
signaling of the OXE-R. Comparison of concentration effect curves of OXE derived from 
OXE-R G16 signaling in DMR and calcium mobilization assays (a) and OXE-R Gi signaling in 
DMR and cAMP assays (b). For OXE-R G16 signaling (a), OXE pEC50 values are: DMR: 5.39 ± 
0.09; calcium: 7.75 ± 0.04, and for OXE-R Gi signaling (b), OXE pEC50 values are: DMR: 6.11 
± 0.21, cAMP: 6.67 ± 0.09. Data are mean ± SEM of at least three independent experiments, 
each performed in triplicates. 
  
The discrepancy between OXE potency in G16 calcium assays and in G16 DMR assays 
might be due to the different cell responses investigated by each method: while second 
messenger assays quantify a defined cellular reaction at an early stage of signaling, 
DMR technology measures the whole-cell response at the end of a signaling cascade, 
comprising more than one cellular event. Hence, agonist potencies derived from DMR 
assays and from second messenger assays can converge, but do not have to. 
Schröder et al. (2010) evaluated the DMR technology against classical second 
messenger assays using a set of GPCRs and their corresponding agonists, and by 
comparing agonist potencies derived from both methods, DMR was found to be as 
sensitive, or even more, than the according second messenger assay. In another study by 
Lee et al. (2008), agonist and antagonist potencies derived from DMR and second 
messenger assays were compared and found to be in good agreement for the most part. 
-12 -10 -8 -6 -4
-20
0
20
40
60
80
100
120
-20
0
20
40
60
80
100
120
DMR
Calcium
OXE (log M)
R
e
la
tiv
e
 r
e
s
p
o
n
s
e
(%
 o
f 
3
0
 µ
M
 O
X
E
) Ca
lc
iu
m
 re
s
p
o
n
s
e
  (%
 o
f 3
0
0
 n
M
 O
X
E
)
G16 Gi
a b
-10 -9 -8 -7 -6 -5 -4
-20
0
20
40
60
80
100
120
-20
0
20
40
60
80
100
120
cAMP
DMR
OXE (log M)
R
e
la
tiv
e
 r
e
s
p
o
n
s
e
(%
 o
f 
1
0
 µ
M
 O
X
E
)
c
A
M
P
(%
 o
f 0
.5
 µ
M
 F
S
K
)
62   3 Results 
Only the agonist potency of one compound, a synthetic D2 receptor agonist, was more 
than 1000-fold decreased in DMR assays compared to cAMP assays when tested on 
CHO-D2 cells. Furthermore, this compound caused DMR responses on CHO-M1 and 
native CHO cells in micromolar concentrations. It was speculated that the compound 
might act unspecific due to activation of unknown pathways, thus leading to 
desensitization of the D2 triggered DMR response of the D2 receptor.  
Since it had been determined that OXE did not induce a DMR response on native 
HEK293 cells (fig. 20c) and thus activation of unknown pathways leading to 
desensitization of the OXE-R can be excluded, the large OXE potency shift between 
G16 DMR and G16 calcium mobilization assays might rather be explained by the fact 
that the G16 pathway is not the native pathway of the OXE-R. Obviously, the quick 
OXE-R G16 response observed for nanomolar OXE concentrations in calcium 
mobilization assays cannot be monitored in DMR assays, proving that the OXE-R G16 
DMR response follows a different concentration-response relationship. 
 
Unfortunately, of the three compounds tested for inhibitory effects on G16 signaling of 
the OXE-R in DMR assays, only Gü 1654 was found to inhibit the OXE triggered DMR 
response, whereas no inhibitory effect could be detected for Gü 1157 and Gü 1158. The 
G16 response of the OXE-R was inhibited by Gü 1654 in a concentration dependent 
manner, while the Gi mediated whole cell response of the OXE-R was not affected by 
this compound. Furthermore, Gü 1654 was found not to inhibit G16 mediated signaling 
of the CRTH2 receptor, proving that Gü 1654 is not a universal G16 inhibitor. Thus, the 
biased antagonism hypothesis was confirmed for at least this compound. 
The next aim of this work was to analyse the OXE-R for recruitment of β-Arrestin and 
to test Gü 1654 for inhibitory activity on OXE-R β-Arrestin recruitment.   
 
 
 
 
 
3 Results 
 
63 
3.4 Investigations of OXE-R β-Arrestin recruitment  
 
Ligand-induced GPCR activation leads to G protein coupling, followed by second 
messenger production and intracellular signaling. Subsequently after receptor 
activation, GPCR kinases (GRKs) phosphorylate the receptor, and cytoplasmic proteins 
called Arrestins, are recruited from the cytoplasm to the cell membrane, where they 
bind to the receptor and hence inhibit further G protein signaling, resulting in 
desensitization of GPCR signaling. Thus, Arrestins play an important role in regulating 
receptor signaling. There are four types of Arrestins, which are also referred to as β-
Arrestins1-4. β-Arrestin3 and 4 are expressed only in retinal rods and cones, whereas β-
Arrestins1 and β-Arrestin2 are ubiquitously expressed. Recently, new roles for β-
Arrestins have been discovered. β-Arrestins are reported to function as scaffold 
proteins, interacting with GPCRs in a G protein-independent manner, by linking them to 
cytosolic proteins triggering intracellular signaling targeting mitogen-activated protein 
kinases (MAPK) like extracellular receptor kinases (ERK) 1/2, as well as JNK3 and p38 
MAPK (Wei et al., 2003; Lutrell and Lefkowitz, 2002). In the present chapter of this 
work, the OXE-R should be analysed for its ability to recruit β-Arrestin in BRET 
assays. Until now, β-Arrestin recruitment of the OXE-R was mentioned only by Vrecl et 
al. (2004). In β-Arrestin translocation BRET assays, Vrecl et al. analysed β-Arrestin 
mutants for enhancement of BRET signals, and the OXE-R TG1019 was used as a 
control receptor, also displaying improved BRET signals with a β-Arrestin 2 mutant. As 
these are the only data in literature concerning β-Arrestin recruitment of the OXE-R, it 
is unclear whether Gi protein activation is needed for β-Arrestin recruitment to the 
OXE-R or if the receptor is also able to recruit β-Arrestin independently from Gi. Thus, 
the OXE-R should be analysed for β-Arrestin recruitment in the presence and absence 
of Gi protein activation. If β-Arrestin recruitment occurred in the absence of Gi 
activation, then Gü 1157, Gü 1158 and Gü 1654 should be tested in BRET assays for 
antagonistic activity on this process.  
For performance of OXE-R β-Arrestin recruitment BRET assays, HEK293 cells stably 
expressing GFP
2
-labeled β-Arrestin2 (HEK-ßARR2-GFP2) were transiently transfected 
with the OXE-R fused to Renilla luciferase (OXE-R-Rluc). BRET assays were carried 
out as described in section 2.2.3.3.  
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3.4.1 Investigations of OXE-R β-Arrestin recruitment 
In BRET assays, at first kinetics of OXE-R β-Arrestin2 recruitment were analysed. 
HEK-βARR2-GFP2 cells transiently expressing the OXE-R fused to Rluc were 
stimulated with 1 µM OXE for 2, 5, 10 and 15 minutes, respectively. Hereafter, 
Coelenterazine a was added and immediately fluorescence was measured. Increased 
BRET ratios of approximately 60 mBRET were gained for all agonist stimulation times, 
as compared to the basal buffer value (fig. 27a).  
Figure 27: OXE-R β-Arrestin2 recruitment is investigated in BRET assays using HEK-
βARR2-GFP2 cells transiently expressing the OXE-R fused to Rluc. (a) BRET signals of 60 
mBRET were obtained after 2,5,10 and 15 minutes of agonist stimulation. (b) β-Arrestin2 
recruitment was not attenuated after Gi inactivation by PTX pre-treatment (50 ng/ml for 18h). 
OXE concentration effect curves were established, yielding OXE pEC50 values of 7.22 ± 0.1 for 
PTX-untreated cells and 7.14 ± 0.11 for PTX-treated cells (b). In (a), representative data (mean 
+ SEM) of three independent experiments are shown, each performed in triplicates. In (b), data 
are mean (± SEM) of at least three independently performed experiments, each in triplicates. 
 
The agonist stimulation time of 10 minutes was chosen for following OXE-R β-
Arrestin2 recruitment BRET assays. An OXE concentration effect curve was 
established by stimulating the cells with increasing concentrations of OXE, yielding an 
OXE pEC50 value of 7.22 ± 0.1 (fig. 27b, black trace).  
In order to determine whether β-Arrestin2 recruitment to the OXE-R occurs 
independently from Gi activation, PTX-treated cells (50 ng/ml, 18 h) were challenged 
with increasing concentrations of OXE (fig. 27b, red trace). Data revealed, that β-
Arrestin2 recruitment to the OXE-R was not attenuated after inactivation of Gi, and 
OXE displayed equal potency (pEC50 = 7.14 ± 0.11), as compared to OXE potency 
derived from non-PTX-treated cells. These data suggest that the OXE-R recruits β-
Arrestin2 independently from Gi protein activation. 
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3.4.2 Investigations of antagonistic activity of Gü 1157,  Gü 1158 and Gü 1654 on 
OXE-R β-Arrestin2 recruitment 
 
Gü 1157, Gü 1158 and Gü 1654 were analysed for inhibitory activity on β-Arrestin2 
recruitment of the OXE-R. Cells were pre-incubated with increasing concentrations of 
compounds, or buffer as control, for 30 minutes and agonist concentration effect curves 
were recorded. Gü 1654 decreased OXE-mediated BRET signals concentration 
dependently by decreasing the maximal response (fig. 28a). Thus, it can be concluded 
that Gü 1654 acts as an insurmountable antagonist on OXE-R β-Arrestin2 recruitment.  
However, Gü 1157 and Gü 1158 led to quenched BRET signals, making it impossible to 
analyse these compounds in BRET assays (data not shown). This phenomenon may be 
due to the light yellow colouring of the Gü 1157 and Gü 1158 stock solutions. Thus, Gü 
1157 and Gü 1158 could not be further evaluated for inhibitory effects on OXE-R β-
Arrestin2 recruitment in BRET assays.   
 
Figure 28: Gü 1654 acts as insurmountable antagonist on OXE-R β-Arrestin2 recruitment. 
HEK-βARR2-GFP2 cells transiently expressing the OXE-R linked to Rluc were incubated with 
Gü 1654 in 3, 10 and 30 µM, respectively, and cells were stimulated with increasing 
concentrations of OXE. Experiments were performed in the absence (a) and presence (b) of 
PTX (50 ng/ml, 18 h). OXE-R β-Arrestin2 recruitment was concentration-dependently inhibited 
by Gü 1654, and in the absence of active Gi proteins, antagonism was even more pronounced 
(b). Data are mean (± SEM) of at least three independently performed experiments, each in 
triplicates. BRET ratio is normalized to the maximal concentration of 3 µM OXE. 
 
Interference of Gü 1654 on OXE-R β-Arrestin2 recruitment in the presence of PTX was 
analysed. OXE concentration effect curves were recorded with PTX-treated cells (50 
ng/ml, 18 h) after pre-incubation with Gü 1654 in increasing concentrations. Gü 1654 
achieved a concentration dependent decrease of the BRET signals (fig. 28b), and it 
could be observed that antagonism of Gü 1654 in 30 µM appeared even more 
pronounced in the presence of PTX, as compared to data from PTX-untreated cells (fig. 
28a).  
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3.4.3 Investigations of the pharmacology of the OXE-R fused to Rluc in DMR 
assays 
The OXE-R fused to Rluc and transiently expressed in HEK293-βARR2-GFP2 cells 
was analysed for its signaling function and pharmacology on the Gi pathway, compared 
to the OXE-R wildtype transiently expressed in HEK293 cells in DMR assays. Cells 
were pre-treated with 30 µM Gü 1654 or buffer, respectively, and increasing 
concentrations of OXE were added in the presence and absence of PTX. Concentration 
effect curves were established, yielding an pEC50 value of 6.1 ± 0.14 for the OXE DMR 
response of the OXE-R-Rluc fusion construct (fig. 29a), which was in good agreement 
with the pEC50 value of 6.1 ± 0.08, obtained from the OXE-R wildtype DMR response 
(fig. 29b). Gi signaling of both constructs was confirmed by the use of PTX (50 ng/ml, 
18 h), which completely abolished the OXE-mediated response. Signaling of OXE-R 
fused to Rluc and of OXE-R wildtype was unaffected by 30 µM Gü 1654. Together, 
OXE-R fusion to Renilla luciferase does not confound the function of the receptor. 
 
Figure 29: Function and pharmacology of the OXE-R when fused to Renilla luciferase is 
compared to the OXE-R wildtype in DMR assays.  DMR responses of HEK293-βARR2-
GFP2 cells transiently expressing the OXE-R fused to Renilla luciferase and HEK293 cells 
transiently expressing the OXE-R wildtype were compared. OXE-mediated responses obtained 
from both the OXE-R-Rluc and the OXE-R wildtype construct were Gi-mediated, as confirmed 
by PTX (50 ng/ml, 18 h) sensitivity, and not affected by 30 µM Gü 1654. The pEC50 values of 
OXE obtained from concentration effect curves were in good agreement (6.1 ± 0.14 for the 
OXE-R fused to Rluc and 6.1 ± 0.08 for the OXE-R wildtype). Data are mean (± SEM) of three 
independent experiments, each performed in triplicates. DMR responses are normalized to the 
maximal concentration of 10 µM OXE. 
 
3.4.4 Investigations of OXE-R specific inhibition of β-Arrestin recruitment by Gü 
1654  
To confirm that Gü 1654 specifically inhibits β-Arrestin2 recruitment of the OXE-R, Gü 
1654 was tested for inhibitory activity on CRTH2 β-Arrestin recruitment in BRET 
assays. G protein-independent β-Arrestin recruitment by the CRTH2 has previously 
been reported by Mathiesen et al. (2005). HEK-βARR2-GFP2-CRTH2-Rluc cells were 
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pre-incubated with increasing concentrations of Gü 1654 or buffer as control, and were 
challenged with 100 µM PGD2. BRET data revealed that PGD2-mediated β-Arrestin2 
recruitment was not inhibited by Gü 1654 (fig. 30). 
 
Figure 30: β-Arrestin2 recruitment of the CRTH2 receptor is not inhibited by Gü 1654. 
After pre-incubation with Gü 1654 in increasing concentrations, stable HEK-ßARR2-GFP2-
CRTH2-Rluc cells were challenged with 100 µM PGD2. Gü 1654 did not inhibit PGD2-
mediated β-Arrestin2 recruitment. Shown are representative data (mean + SEM) of three 
independent experiments, each performed in duplicates. 
 
It is concluded that Gü 1654 is indeed a specific inhibitor for the OXE-R since it does 
not interfere with β-Arrestin2 translocation of the CRTH2.   
3.4.5 Discussion 
In the present chapter, investigations on β-Arrestin recruitment of the OXE-R in BRET 
assays are presented. β-Arrestins are cytoplasmic proteins whose function was first 
found to be terminating GPCR signaling. Nowadays, new findings have emerged 
concerning functions of β-Arrestins. There is evidence that termination of G protein 
coupling of some GPCRs can occur independently from GRK phosphorylation and β-
Arrestin recruitment (Mathiesen et al., 2005), (Shenoy et al., 2006), moreover, β-
Arrestins were discovered to mediate signaling of some GPCRs independently from G 
proteins by acting as scaffolds, linking the receptor to G protein-independent pathways 
such as ERK1/2 MAP kinases (Azzi et al., 2003; Wei et al., 2003; Mathiesen et al., 
2005). Interestingly, ligands have been reported to act in a biased fashion on GPCR 
signaling by selectively inducing β-Arrestin-mediated, but not G protein-mediated 
signaling (Gesty-Palmer et al., 2006), and only recently, a GPCR has been reported to 
signal exclusively through β-Arrestin without detectable G protein activation (Rajagopal 
et al., 2010). Furthermore, a biased fashion of antagonism has been described for 
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antagonists, exhibiting antagonism selectively on β-Arrestin recruitment but not on G 
protein activation (Mathiesen et al., 2005). 
 
A first hint for β-Arrestin recruitment of the OXE-R was given in a study by Vrecl et al. 
(2004), but as in this work only briefly β-Arrestin recruitment by the OXE-R was 
depicted in a control experiment verifying previous findings on a β-Arrestin mutant. 
The mechanism underlying OXE-R β-Arrestin recruitment would remain unclear.  
In this work, OXE-R β-Arrestin recruitment was analysed in β-Arrestin  translocation 
BRET assays, and for the first time it could be demonstrated that the OXE-R recruits    
β-Arrestin independently from Gi activation. Control experiments in DMR assays 
proved unaltered function and pharmacology of the OXE-R-Rluc fusion construct, as 
compared to the OXE-R wildtype. Cell pre-treatment with PTX silenced the DMR 
response of both OXE-R constructs, proving the OXE triggered response to be Gi-
mediated. In addition, the abolished Gi DMR response of HEK293-βARR2-GFP
2
 cells 
transiently expressing the OXE-R-Rluc proved evidence that Gi was indeed silenced in 
these cells after the same PTX-treatment in β-Arrestin translocation BRET assays.  
Moreover, the PTX experiment using HEK293-βARR2-GFP2 cells transiently 
expressing the OXE-R fused to Rluc revealed another important finding: As no DMR 
signal could be observed in the presence of PTX, while in BRET assays with the same 
cells and the same PTX pre-treatment β-Arrestin translocation was obtained, data 
revealed that β-Arrestin recruitment cannot be captured by DMR technology. 
Gü 1157, Gü 1158 and Gü 1654 were tested in β-Arrestin recruitment BRET assays on 
the OXE-R. Unfortunately, Gü 1157 and Gü 1158 could not be analysed for inhibitory 
effects on OXE-R β-Arrestin recruitment in BRET assays, as fluorescence signals were 
quenched likely due to the yellow colour of the compounds. Gü 1654 exhibited        
insurmountable antagonism on OXE-R β-Arrestin recruitment in both PTX-treated and 
untreated cells.   
The finding that the OXE-R recruits β-Arrestin independently from Gi proteins,        
suggests that the OXE-R might utilize β-Arrestin as a scaffold for cellular signaling.  
Until now, β-Arrestin signaling of the OXE-R has not been analysed or described in the 
literature yet.  
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Studies on general physiological effects related to β-Arrestin signaling have found       
β-Arrestin to exhibit regulatory functions relevant for cell proliferation (Kim et al., 
2008) and heart disease (Noma et al., 2007). Furthermore, β-Arrestin2 was determined 
to be involved in chemotaxis, as this was demonstrated for the CXCR4 receptor in HeLa 
and HEK293 cells by Sun et al. (2002). Similar observations have been made by Fong 
et al. (2002), as they showed that lymphocytes derived from β-Arrestin knock-out mice 
were impaired in their ability to perform chemotaxis toward a chemotactic gradient. In 
addition, allergen-sensitized mice lacking β-Arrestin in T cells appeared not to exhibit  
physiological or inflammatory responses characteristic for asthma (Walker et al., 2003), 
providing evidence that β-Arrestin2 has a regulatory function for the development of 
allergic inflammation.  
As these findings imply a role for β-Arrestins contributing to cell chemotaxis and to 
inflammatory processes, it is likely that β-Arrestins might be involved in OXE triggered 
chemotaxis of neutrophils and eosinophils. In conclusion, OXE-R signaling through β-
Arrestin needs to be explored in the future. Evaluation of physiologic or               
pathophysiologic roles of OXE-R β-Arrestin signaling could be performed by using 
eosinophils and neutrophils derived from β-Arrestin knock-out mice, e.g. by analysing 
if these cells have lost their ability to undergo chemotaxis in response to OXE. If OXE 
triggered chemotaxis of neutrophils and eosinophils turned out to be β-Arrestin-related, 
Gü 1654 could be a valuable tool to study the pathophysiological role of OXE-R β-
Arrestin signaling in asthma or other allergic diseases. 
70   3 Results 
3.5 Investigations of antagonistic activity of Gü 1654 on OXE-R 
signaling in human primary cells 
 
In cAMP second messenger and DMR assays, Gü 1654 was found to be a selective 
OXE-R antagonist, competent to discriminate between Gi and G16 signaling of the 
OXE-R. As these findings were observed in recombinant cells overexpressing the OXE-
R, it was of great interest to analyse Gü 1654 for inhibitory activity on OXE-R signaling 
in primary cells and to test, if the compound would retain its ability to discriminate 
between Gi and non-Gi signaling.  
The OXE-R is highly expressed in peripheral leukocytes, lung, kidney, liver and spleen 
(Hosoi et al., 2002; Jones et al., 2003). As signaling of endogenously expressed OXE-R 
is mostly analysed in eosinophils and neutrophils, which is due to the high expression of 
the OXE-R in these cells (Jones et al., 2003; Sturm et al., 2005), eosinophils and 
neutrophils were selected for analysis of Gü 1654 on OXE-R signaling in primary cells.  
 
O´Flaherty et al. (1996) reported OXE-mediated calcium flux in neutrophils and 
eosinophils to be PTX sensitive, indicating that OXE-mediated calcium flux is triggered 
by Gi signaling of the OXE-R in these cells. Thus, calcium flux assays provided the 
opportunity to analyse the influence of Gü 1654 on the OXE-R Gi pathway.  
Analysis of Gü 1654 on OXE-R signaling through another pathway than Gi was 
attempted to be achieved by DMR assays. Because DMR signals capture the holistic 
response of a cell, the use of DMR technology was expected to uncover OXE-R 
signaling beyond the Gi pathway. 
The consideration to utilize DMR assays for analysis of OXE-R signaling in neutrophils 
was supported by DMR data generated by Kathy Dodgson (Astra Zeneca), presenting 
DMR responses of neutrophils challenged with Interleukin-8, proving that DMR assays 
offer a chance for the analysis of GPCR signaling in neutrophils.  
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3.5.1 Investigations   of   antagonistic  activity   of   Gü  1654   on  the  OXE-R  in 
neutrophil DMR assays  
3.5.1.1 Development of a neutrophil DMR assay 
 
Neutrophil data generated by Kathy Dodgson (Astra Zeneca) showed that neutrophils 
responded with a positive and concentration dependent DMR response to Interleukin-8 
(IL-8), the agonist of in neutrophils endogenously expressed chemokine receptors 
CXCR1 and 2  (fig. 31). The IL-8 concentration effect curve generated from these data 
yielded an EC50 value of 1 nM.  
 
Figure 31: Neutrophils display concentration dependent DMR responses upon 
stimulaton with IL-8. The image was taken from the ELRIG presentation “Application 
of the Corning
®
 Epic
®
 System to label-free functional GPCR assays, Kathy Dodgson, 
Lead Generation Biology, AstraZeneca R&D Charnwood”. 
 
Based on these results, IL-8 was chosen as positive control for neutrophil DMR assays. 
Nicotinic acid was also chosen as control, as expression and functionality of the 
nicotinic acid receptor HM74A in neutrophils was described by Kostylina et al. (2008).  
Peripheral blood from healthy volunteers was collected according to a protocol 
approved by the Ethics Committee of the medical faculty of the University of Bonn. All 
volunteers provided informed consent. Neutrophils were isolated from peripheral blood 
as described in section 2.2.2.8 and cells were seeded with a cell density of 65.000 cells 
per well into an uncoated biosensor microplate. Because neutrophils are easily activated 
and therefore should be used within the next few hours after isolation from blood, a 
short assay pre-incubation time of ten minutes was chosen. During pre-incubation, a 
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baseline read was performed to control cell reactions, displaying a steady baseline 
signal that revealed no DMR neutrophil response (fig. 32a). IL-8, NA and OXE were 
added in various concentrations to the cells, and the neutrophil DMR response was 
recorded. Remarkably, and in contrast to the neutrophil IL-8 DMR data presented by 
Kathy Dodgson, negative DMR responses were obtained for IL-8 (fig. 32b). A negative 
DMR signal was also obtained for NA (fig. 32c), and unfortunately, no DMR response 
was recorded for OXE (fig. 32d).  
 
Figure 32: Analysis of neutrophils for DMR responses after stimulation with IL-8, NA and 
OXE. Neutrophils were seeded into an uncoated biosensor microplate at a cell density of 65.000 
cells per well, and DMR responses were analysed during 10 minutes incubation prior to the 
assay (a). Negative DMR responses were recorded after cell stimulation with IL-8 (b) and NA 
(c), and no change in baseline signals was recorded after stimulation with OXE (d). Shown are 
data of one experiment (+ SEM) performed in triplicates.   
 
In order to test if a positive DMR response could be obtained by another cell number, 
different cell numbers of 40.000, 50.000 and 60.000 neutrophils per well were tested in 
the next experiment. Still, negative DMR responses upon stimulation with IL-8 were 
recorded for all cell numbers (fig. 33a,b,c).  
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Figure 33: The neutrophil DMR response to IL-8 was analysed using different cell 
numbers. Neutrophils seeded into an uncoated biosensor microplate at cell numbers of 40.000 
(a), 50.000 (b) and 60.000 (c) cells per well were stimulated with IL-8. At all cell numbers, cells 
responded with a negative DMR response. Depicted are data of one experiment (+ SEM) 
performed in triplicates.   
  
Because at 60.000 cells per well (fig. 33c) the neutrophil DMR response was observed 
to correspond to the IL-8 concentrations for the most part, this cell number was        
determined to be used for further experiments. Neutrophil DMR assays were repeated 
with various incubation times for several experiments to obtain positive neutrophil 
DMR responses, but although neutrophil isolation and DMR assay conditions were   
consistent with the protocols used by Kathy Dodgson (personal communication), still 
negative DMR responses to IL-8 remained (data not shown). Because negative DMRs 
can indicate cell detachment from the well bottom of the biosensor microplate, in a   
further experiment neutrophils were seeded into a fibronectin-coated biosensor         
microplate to enhance cell attachment to the plate bottom. To control cell reactions due 
to eventual activation by the fibronectin coating, a baseline read was performed during 
assay pre-incubation of 50 minutes. Indeed, a positive DMR up to 200 pm was         
observed, which decreased after 600 seconds and changed into a negative DMR (fig. 
34a). In this assay, IL-8 still induced a negative DMR response (fig. 34c), but for the 
first time, a positive DMR response was obtained for NA (fig. 34b). OXE was not 
applied in this assay. 
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Figure 34: Neutrophil DMR assay using fibronectin-coated biosensor microplates displays 
a positive DMR for NA. Neutrophils seeded into a fibronectin-coated biosensor microplate 
showed a positive DMR response during incubation of 50 minutes prior to the assay (a). For the 
first time, NA triggered a positive neutrophil DMR response (b), whereas the DMR response to 
IL-8 remained negative (c). Shown are data of a single experiment (+ SEM) performed in 
triplicates.   
 
In the following experiment using fibronectin-coated biosensor microplates, neutrophils 
were incubated for 2 hours. Again, cells reacted to fibronectin inducing a positive 
DMR, but the fibronectin-triggered DMR response declined and stabilized after 2000 
seconds (fig. 35a). After compound addition, for the first time all agonists induced 
positive DMR responses. At the positive DMR response for IL-8 (fig. 35c), signals 
increased concentration dependently and an IL-8 concentration effect curve was 
generated (fig. 35d), yielding a pEC50 value of 8.35 ± 0.06, which was in good 
agreement with the IL-8 data by Kathy Dodgson (fig. 31). Neutrophils also responded 
with a positive and concentration dependent DMR signal to NA, from which a 
concentration effect curve was established, yielding a pEC50 of 6.34 ± 0.10 (fig. 35e). 
Surprisingly, cells treated with OXE in various concentrations only responded to the 
highest agonist concentration of 30 µM, resulting in a positive DMR signal (fig. 35b). 
At lower OXE concentrations, no DMR response could be detected. 
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Figure 35: Neutrophils display positive DMR signals after pre-incubation for 2h on 
fibronectin- coated biosensor microplates. During 2 hours incubation prior to the assay, a 
positive DMR response was observed, which declined and stabilized after 30 minutes (a). Cells 
responded with positive DMR signals upon agonist stimulation. Signals for IL-8 (c) and NA (e) 
were concentration dependent, whereas OXE triggered a DMR signal only at 30 µM (b). The 
pEC50 values are: 8.35 ± 0.06 for Il-8 (d) and 6.34 ± 0.10 for NA (f). Shown is representative 
data from three independent experiments (+ SEM and mean values), performed in triplicates. 
  
The finding that a neutrophil DMR response could be obtained only at 30 µM OXE was 
confirmed in several additional assays, where it would remain unclear, why cells did not 
respond to lower OXE concentrations, while at the same time robust neutrophil 
responses were obtained for IL-8 and NA at various concentrations.  
In calcium flux Gi assays, neutrophil responses due to OXE stimulation are obtained by 
OXE concentrations ranging from 1 nM to 1 µM (Sturm et al., 2005). Thus, the 
concentration of 30 µM OXE was fairly high, and it was suggested that the DMR signal 
obtained at 30 µM OXE might not be mediated by Gi signaling of the OXE-R but by 
signaling through another pathway. Moreover, it was suggested that this signal might 
also result from an unspecific cell response triggered by the high OXE concentration.  
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3.5.1.2 Investigations of inhibitory acitivity of Gü 1654 on the neutrophil DMR 
response at 30 µM OXE  
To evaluate if the DMR signal at 30 µM OXE was produced due to an unspecific cell 
response triggered by the high OXE concentration, or if the DMR signal might indeed 
result from OXE-R signaling by another but the Gi pathway, it was analysed if Gü 1654 
was able to inhibit the neutrophil DMR response obtained at 30 µM OXE.  
Neutrophils were pre-incubated with 30 µM Gü 1654 or buffer as control during the last 
30 minutes of a pre-incubation time of 2h, where it could be observed that Gü 1654 did 
not trigger unspecific neutrophil DMR responses (fig. 36a). Remarkably, after addition 
of OXE to the cells, no DMR response was recorded for cells pre-incubated with Gü 
1654 (fig. 36b). A DMSO control containing the same DMSO concentration as the 
buffered solution of Gü 1654 proved, that DMSO did not affect the OXE mediated 
neutrophil response (fig. 36b).  
Thus, it was concluded that the abrogated OXE DMR response after pre-incubation with 
Gü 1654 resulted from inhibitory effects of Gü 1654 and was not due to restricted cell 
responsiveness caused by DMSO. The inhibitory effect on the 30 µM OXE neutrophil 
DMR response was also determined for Gü 1654 in 10 µM (fig. 36c). 
 
 
3 Results 
 
77 
 
Figure 36: Gü 1654 was analysed for inhibitory effects on the neutrophil DMR response at        
30 µM OXE. Neutrophils did not respond to Gü 1654 during pre-incubation for 30 minutes (a). 
The OXE-mediated neutrophil DMR response was inhibited at 30 µM Gü 1654 (b) and 10 µM 
Gü 1654 (c). Specific inhibition of the OXE-mediated DMR response by Gü 1654 was analysed 
at the NA-mediated response: 10 µM Gü 1654 did not inhibit the NA DMR response (e), 
whereas 30 µM Gü 1654 could not be analysed due to DMSO interference with the NA-
mediated DMR response (d). Shown are representative data (mean + SEM) of one experiment 
(d), two experiments (c), and three experiments (a,b,e). Each experiment was performed in 
triplicates.  
 
The specificity of the inhibitory effect of Gü 1654 on the OXE-mediated cell response 
was analysed on the neutrophil response mediated by NA. The DMSO control, which 
was also used here, revealed that the NA-mediated DMR response of neutrophils was 
sensitive to DMSO at a concentration of 0.48 % (fig. 36d). Hence, Gü 1654 was 
difficult to analyse in   30 µM on the NA neutrophil response.  
Analysis of Gü 1654 in 10 µM revealed no antagonistic effects for Gü 1654 on the NA-
mediated DMR (fig. 36e) and no interaction with the DMSO concentration of 0.16 %, 
as confirmed by three independent experiments. Thus, specific inhibition of the OXE-
mediated DMR response by Gü 1654 could be determined for at least 10 µM Gü 1654. 
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Based on these results, it was suggested that the neutrophil DMR response at 30 µM 
OXE was mediated by the OXE-R, as this response was shown to be specifically 
inhibited by Gü 1654. Also, it was suggested that the neutrophil DMR response at 30 
µM OXE resulted from another but the OXE-R Gi pathway. Additional investigations 
on the OXE-mediated neutrophil DMR response were not performed. DMR assays 
might be a valuable tool to study signaling of receptors activated by IL-8 or NA in 
neutrophils, but, however, these assays were determined not to constitute an appropriate 
method to study OXE-R signaling in neutrophils. Further analysis of OXE-R signaling 
and inhibitory activity of Gü 1654 on OXE-R signaling in primary cells should be 
performed using assays approved for analysis of GPCR signaling in leukocytes. 
 
3.5.2 Analysis of Gü 1654 on Gi-mediated signaling of the OXE-R in human 
primary cells 
It was decided to analyse Gü 1654 in calcium mobilization assays using eosinophils and 
neutrophils in order to investigate if the compound has any influence on the Gi-mediated 
calcium flux in these primary cells or if Gü 1654 would retain its biased antagonism on 
OXE-R signaling by showing no inhibition of Gi coupling.   
Calcium flux assays on eosinophils and neutrophils were performed by Petra Luschnig 
from the group of Akos Heinemann, Institute of Experimental and Clinical             
Pharmacology, Medical University of Graz, Graz, Austria.  
 
3.5.2.1 Investigations of antagonistic activity of Gü 1654 on OXE-R Gi mediated 
calcium flux in eosinophils and neutrophils  
OXE-triggered calcium flux in eosinophils (fig. 37a) and neutrophils (fig. 37c) was 
confirmed to be Gi-mediated, as calcium flux was abrogated after cell pre-treatment 
with PTX (3 µg/ml, 1 h). Cell viability after PTX treatment was confirmed by the 
Calciumionophore (fig. 37b,d), which increases intracellular calcium ions in intact cells 
and forms stable complexes with divalent cations. 
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Figure 37: OXE-mediated eosinophil and neutrophil calcium flux is Gi-mediated. 
Eosinophil (a) and neutrophil (c) calcium flux upon OXE stimulation was found to be PTX 
sensitive, and thus Gi mediated. Cells were treated with 3 µM PTX for 1 h. Viability of both 
eosinophils (b) and neutrophils (d) after PTX-treatment was confirmed by 300 nM 
Calciumionophore. Data presented are mean (+ SEM) of four independent experiments, each 
performed in triplicates. 
  
Gü 1654 was tested for antagonistic activity on Gi-mediated calcium flux in eosinophils 
and neutrophils. After pre-incubating the cells with 1 µM Gü 1654 for 15 minutes, 
calcium flux assays were performed as described by Heinemann et al. (2003). 
Unexpectedly, eosinophil (fig. 38a) and neutrophil calcium flux (fig. 38b) was 
completely abrogated at 1 µM Gü 1654.  
 
 
 
 
Neutrophils
-10 -9 -8 -7 -6 -5
50
150
250
350
450
 - PTX
+ PTX
OXE (log M)
%
 b
a
s
is
Eosinophils
-10 -9 -8 -7 -6 -5
50
150
250
350
450
 - PTX
+ PTX
OXE (log M)
%
 b
a
s
is
Neutrophils
- PTX + PTX
50
150
250
350
450
550
Calciumionophore 300 nM
%
 b
a
s
is
Eosinophils
- PTX + PTX 
50
150
250
350
450
Calciumionophore 300 nM
%
 b
a
s
is
a b
c d
80   3 Results 
 
Figure 38: 1 µM Gü 1654 completely inhibits OXE-mediated calcium flux in eosinophils 
and neutrophils. After pre-incubation with 1 µM Gü 1654 or buffer as control, eosinophils (a) 
and neutrophils (b) were challenged with increasing concentrations of OXE. Calcium flux of 
both eosinophils and neutrophils was completely abolished by Gü 1654. Specificity of Gü 1654 
on the OXE-mediated calcium flux was confirmed on IL-8-mediated calcium flux in eosinophils 
(c) and neutrophils (d), which was not attenuated after pre-incubation with 1 µM Gü 1654.  
 
To prove receptor specificity of inhibition with Gü 1654, the compound was analysed at 
Gi-mediated, IL-8 triggered calcium flux of eosinophils and neutrophils (Kernen et al., 
1991). IL-8 triggered calcium flux of eosinophils (fig. 38c) and neutrophils (fig. 38d) 
was not affected by Gü 1654. 
 
The finding, that Gü 1654 inhibited OXE-R Gi signaling in human primary cells 
appeared contrary to the findings obtained from cAMP accumulation and DMR assays 
with HEK293 cells overexpressing the OXE-R, where Gü 1654 was determined not to 
exhibit antagonism on the OXE-R Gi pathway. Thus, it was initially suggested that Gü 
1654 does not maintain its ability to discriminate between the OXE-R signaling via the 
Gi pathway or another pathway in human primary cells.   
However, by comparing the results from cAMP accumulation assays to the results from 
primary cell calcium flux assays, it became apparent, that, although in both assays Gi 
signaling of the OXE-R was measured, the recorded Gi signaling in the two different 
readouts is mediated by two different Gi protein signaling mechanisms: While inhibition 
of adenylyl cyclase is mediated by Gαi subunits of activated heterotrimeric Gi proteins 
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(Moxham et al., 1993; Sunahara et al., 1996), calcium flux is mediated by Gβγ subunits 
of the same activated heterotrimeric Gi protein (Morris and Scarlata, 1996; Hall et al., 
1999. Hosoi et al., 2005).  
In conclusion, it was suggested that Gü 1654 appeared to exhibit a selective antagonism 
on OXE-R signaling in leukocytes, by inhibiting receptor signaling via Gβγ subunits but 
not via Gαi subunits. This putative new mechanism of biased receptor antagonism has 
not yet been described in literature.  
In order to prove this notion, Gü 1654 was tested for antagonism on neutrophil OXE-R 
Gαi signaling recorded in cAMP accumulation assays. 
 
3.5.2.2 Investigations of antagonistic activity of  Gü 1654 on Gαi signaling of the   
OXE-R in neutrophils using cAMP accumulation assays 
 
Analysis of Gü 1654 on Gαi signaling of in neutrophils endogenously expressed     
OXE-R was performed in cAMP accumulation assays using the LANCE Ultra cAMP 
kit (Perkin Elmer), as described in section 2.3.2.  
 
3.5.2.2.1 Validation of cAMP assay in neutrophils 
In order to determine the dynamic range of the LANCE Ultra cAMP assay, a cAMP 
standard curve was generated according to the LANCE Ultra cAMP assay development 
guidelines. cAMP standard serial solutions were prepared from a cAMP standard and 
TR-FRET was detected. A cAMP standard curve was established, and the dynamic 
range was located between -9.45 (IC90) and -8.34 (IC10) (fig. 39a).   
To determine the optimal cell density to be used in cAMP accumulation assays, 
forskolin concentration effect curves were generated after 30 minutes of forskolin 
stimulation using different neutrophil cell densities. The obtained forskolin 
concentration effect curves were related to the cAMP standard curve. All tested cell 
numbers provided a response that covered the dynamic range of the cAMP standard 
curve. Increasing cell numbers yielded an increased assay window with the optimal cell 
number of 12.000 cell per well while staying within the dynamic range of the cAMP 
standard curve (fig. 39b,c).  
82   3 Results 
 
Figure 39: Determination of the dynamic range and the optimal cell number for LANCE 
Ultra cAMP assays. (a) A cAMP standard curve was established, and the dynamic range was 
located between -9.45 (IC90) and -8.34 (IC10). (b,c) In forskolin concentration effect curves, the 
highest assay window was gained at a cell number of 12.000 cells per well, which proved to be 
the optimal cell number for neutrophils in LANCE Ultra cAMP assays. Presented data are from 
a single experiment   (+ SEM and mean values, c ± SEM) performed in triplicates.   
 
The optimal cell density used in subsequent experiments was determined to be 12.000 
neutrophils per well, since at this cell density the maximal assay window was obtained. 
For adenylyl cyclase stimulation, the optimal forskolin concentration was determined to 
be 10 µM.  
 
3.5.2.2.2 Analysis of OXE-R Gαi signaling in neutrophils using cAMP accumulation 
assays 
Neutrophils were analyzed for OXE-mediated inhibition of forskolin-stimulated 
adenylyl cyclase. In order to investigate if inhibition occurs in a time dependent manner, 
as it was determined for nicotinic acid-mediated inhibition of forskolin-stimulated 
adenylyl cyclase (Kostylina et al., 2008), cells were stimulated with agonist for 10 and 
30 minutes. 
No concentration corresponding inhibition of forskolin stimulated adenylyl cyclase 
could be determined after neutrophil stimulation with increasing concentrations of OXE 
for 10 minutes (fig. 40a), whereas a concentration dependent inhibition of forskolin-
stimulated adenylyl cyclase was observed after cell stimulation with OXE for 30 
minutes (fig. 40b).  
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Figure 40: Determination of OXE-mediated inhibition of forskolin-stimulated adenylyl 
cyclase in neutrophil cAMP accumulation assays. Concentration dependent inbibition of 
forskolin stimulated adenylyl cyclase was not achieved after 10 minutes stimulation with OXE 
(a), but after 30 minutes (b). Presented data are from a single experiment (+ SEM and mean 
values), each performed in triplicates.   
 
3.5.2.2.3 Analysis of   inhibitory   activity  of  Gü 1654  on  OXE-R  Gαi  signaling  
in neutrophils using cAMP accumulation assays  
Prior to antagonism experiments on OXE-R Gαi signaling in neutrophils, Gü 1654 was 
tested in 30 µM for unspecific effects on neutrophils in cAMP accumulation assays after 
15 minutes cell pre-incubation. For cells treated with Gü 1654, no adenylyl cyclase 
stimulating or inhibiting effects were observed (fig. 41a). Subsequently, Gü 1654 was 
tested at 30 µM for antagonistic acitivity on OXE-R Gαi signaling in cAMP 
accumulation assays. Data revealed that OXE-mediated inhibition of forskolin-
stimulated adenylyl cyclase was not inhibited by 30 µM Gü 1654 (fig. 41b), thus 
confirming the notion that the compound does not inhibit OXE-R Gαi signaling.  
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Figure 41: Analysis of inhibitory activity of Gü 1654 on OXE-mediated Gαi signaling in 
neutrophils. Gü 1654 was found neither to stimulate nor to inhibit adenylyl cyclase activity (a). 
No inhibitory effect on OXE triggered and Gαi-mediated inhibition of forskolin-stimulated 
adenylyl cyclase was detected for Gü 1654 in 30 µM (b). (a) presents data of a single 
experiments (+ SEM and mean values) performed in triplicates, and (b) presents mean data (± 
SEM) of four to five independent experiments, each performed in triplicates.     
 
In conclusion, the initial hypothesis that Gü 1654 acts as biased OXE-R antagonist, with 
inhibitory activity on G16, but not on Gi signaling (section 3.2.2 and 3.3.3), was 
extended for the finding, that Gü 1654 is an OXE-R antagonist competent to 
discriminate between OXE-R signaling via the Gβγ subunit and OXE-R signaling by 
the Gαi subunit of the same heterotrimeric Gi protein.  
It was suggested that these findings uncovered a new mechanism of ligand bias. 
3.5.3 Discussion  
Analysis of Gü 1654 at OXE-mediated calcium flux in eosinophils and neutrophils 
uncovered Gü 1654 to inhibit OXE-R signaling via Gβγ subunits, while preserving 
OXE-R coupling to Gαi subunits of the same heterotrimeric Gi protein. Thus, Gü 1654 
was elucidated not to confer biased antagonism on OXE-R signaling via different G 
protein subfamilies – as previously suggested – but on OXE-R signaling by 
discriminating between the Gα and Gβγ of Gi proteins. 
 
Strikingly, although in neutrophil cAMP accumulation assays Gü 1654 did not affect 
Gαi mediated inhibition of cAMP production at the highest concentration of 30 µM - 
which confirmed the results from HEK293 cell cAMP accumulation assays with 
overexpressed OXE-R from section 3.2.2 -, Gβγ-mediated calcium flux was already 
completely abolished by Gü 1654 at a concentration of 1 µM. These findings implied 
that OXE-R signaling via the Gi protein subunits Gαi and Gβγ might be modulated 
differentially. Indeed, differential modulation of Gαi and Gβγ effects is not 
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unprecedented in the literature. About two decades ago, Ashkenazi et al. (1997) 
appreciated that the muscarinic acetylcholine receptor M2 inhibits adenylyl cyclase and 
stimulates inositol phosphate (IP) accumulation, and that both processes were mediated 
via Gi proteins, as evidenced by their sensitivity to PTX pre-treatment. Intriguingly, 
however, the adenylyl cyclase response was about 10-fold more sensitive to PTX as 
compared with the IP response. The authors suggested that both effects are differentially 
coupled via the same G protein. Indeed, inhibition of adenylyl cyclase is mediated via 
Gαi subunits whereas phosphoinositide hydrolysis is mediated by Gβγ subunits 
“released” upon Gαiβγ activation (Camps et al., 1992; Katz et al., 1992). Thereforee, 
these data provide support for the notion that Gα responses can be differentially 
modulated over Gβγ responses. 
 
In a further assay, performed by Andreas Bock from the group of Prof. Mohr, 
Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, 
selective inhibition of Gβγ signaling of the OXE-R by Gü 1654 was ascertained.  
In order to exclusively monitor a Gβγ-mediated downstream event, HEK293 cells were 
transiently transfected to co-express the OXE-R, Gβ1 and Gγ2, respectively, and Gβγ-
mediated inositol phosphate 1 (IP1) production was quantified as a measure of receptor 
activity. OXE-triggered IP production was highly significant and mediated by Gβγ, 
since pre-treatment with the small molecule Gβγ inhibitor Gallein (Bonacci et al., 2006) 
completely abolished the response (fig. 42). Gallein, conversely, hardly affected IP1 
accumulation induced upon stimulation of endogenous Gq-linked muscarinic receptors 
-mediated cellular responses (Bonacci et 
al., 2006). Gü1654, which proved to be ineffective when applied alone, completely 
abrogated OXE-R-mediated IP production, but had no impact on IP1 levels triggered by 
stimulation of endogenous Gq-linked muscarinic receptors, confirming that inhibition of 
IP1 production is specific to the OXE-R.  
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Figure 42: Effects of OXE and carbachol on IP1 generation and their sensitivity to Gallein 
and Gü 1654 in HEK293 cells transiently expressing the OXE-R, Gβ1 and Gγ2. Shown are 
mean values  SEM of 3-8 independent experiments each performed in quadruplicate. ***, 
significant effect to basal IP1 levels; 
###
, significant effect to OXE; 
§§§
, significant effect to 
carbachol; ns, non-significant effect to carbachol. ***, 
###
 and 
§§§
, p < 0.001 according to one-
way ANOVA with Bonferroni’s multiple comparison test. Data was kindly provided by 
Andreas Bock. 
 
Since no DMR responses could be monitored upon neutrophil stimulation with 
nanomolar concentrations of OXE, and compared with neutrophil calcium flux and 
cAMP accumulation assays where OXE in equal concentrations produced robust Gβγ 
and Gαi-mediated responses, respectively, it can be suggested that in DMR assays 
neither OXE-R Gβγ nor Gαi signaling can be detected. In neutrophil cAMP 
accumulation assays, OXE-R Gαi signaling results in inhibition of cAMP production, 
but, however, OXE-R Gαi signaling might probably not result in cellular mass 
redistribution and  therefore cannot be detected by DMR technology. Obviously, OXE-
R Gβγ signaling does not trigger DMR reactions either. However, signaling via Gβγ 
subunits released from activated Gi proteins appears to be a crucial mechanism for 
OXE-R signaling, in neutrophils as well as in other types of leukocytes (Grant and 
Powell, 2009).  
 
Originally, G protein βγ subunits were thought to function as terminators of               
Gα-dependent signaling and to prevent spontaneous Gα activation in the absence of 
receptor stimulation (Neer, 1995), until Gβγ was found to activate muscarinic K+ ion 
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channels in cardiac atrial cells (Logothetis et al., 1987). Nowadays, Gβγ subunits are 
known to activate various effectors, such as phospholipase C (PLC) β2 (Katz et al., 
1992; Sternweis, 1994), adenylyl cyclase (Tang and Gilman, 1991), phosphoinositide  
3-kinase (Stephens et al., 1994, Tang and Downes, 1997), and K
+
 and Ca
2+
 channels 
(Logothetis et al., 1987, Reuveny et al., 1994), to name just a few.  
Gi protein expression is high and abundant compared with G proteins from other  G 
protein subfamilies, so that the most part of released Gβγ subunits and subsequent 
signaling of Gβγ is due to Gi protein activation (Clapham and Neer, 1997). Downstream 
signaling of Gβγ subunits released from G proteins can be attenuated by the Gβγ     
scavenger Gtα, the alpha subunit of transducin (Federman et al., 1992; Ho et al., 1999), 
or by small molecule Gβγ inhibitors (Bonacchi et al., 2006). By using these Gβγ 
inhibitors, it could be shown that Gβγ subunits released from chemoattractant Gi 
coupled receptors are essential for cell chemotaxis (Neptune and Bourne, 1997; 
Neptune et al., 1999), and neutrophil-dependent inflammation (Lehmann et al., 2007). 
Signaling by Gβγ subunits has also been reported to be involved in the progression of 
heart failure (Casey et al., 2010) and in proliferation of the breast cancer cells MDA-
MB-231 (Tang et al., 2011). These findings clearly imply a need for therapeutics 
focusing on inhibition of Gβγ signaling related to disease development.    
Two of these Gβγ involved diseases have been reported to be related to OXE-R 
signaling: Inflammation and cancer. As it is largely known, the chemoattractant OXE-R 
is expressed on most immune cells and plays a pivotal role in inflammatory reactions 
(Jones, 2005; Grant and Powell, 2009). Tumor cell proliferation upon OXE stimulation 
was determined for the breast cancer cell lines MDA-MB-231, MCF7, and SKOV3 
(O´Flaherty et al., 2005) and the prostate cancer cell line PC3 (Ghosh and Myers, 1997). 
OXE-R expression in the breast cancer cell lines was determined by mRNA expression 
(O´Flaherty et al., 2005), and OXE-R expression in PC3 cells was determined by the 
use of short-interfering RNA (Sundaram and Ghosh 2006). In conclusion, the finding 
that Gü 1654 specifically inhibits OXE mediated Gβγ signaling of the OXE-R implies 
high impact on Gü 1654 to be used as a valuable tool in trials on OXE mediated       
inflammatory events and OXE-mediated tumor cell proliferation. 
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The aim of the present work was to discover small molecule OXE-R antagonists, to 
characterize the antagonistic activity of the compounds on the different signaling 
pathways of the OXE-R, and finally to determine the antagonistic activity in primary 
cells endogeneously expressing the OXE-R. By use of a biomolecular screening in 
combination with a virtual screening one compound, Gü 1654, was found to exhibit 
specific antagonism on G16 signaling of the OXE-R when over-expressed in HEK293 
cells. Furthermore, antagonistic activity on OXE-R-mediated β-Arrestin2 recruitment 
could also be determined for Gü 1654 in HEK293 cells. However, this compound was 
found to exhibit a biased antagonism, because in cAMP accumulation assays using 
HEK293 cells Gü 1654 did not retain its antagonistic activity on Gi signaling. Finally, 
and most intriguing, when Gü 1654 was tested for antagonistic activity on OXE-R Gi 
signaling in human primary cells, antagonism of Gü 1654 was elucidated to selectively 
inhibit OXE-R Gβγ but not OXE-R Gαi signaling. Thus, Gü 1654 was identified as 
biased antagonist discriminating between OXE-R signaling via different G protein 
subunits of the same G protein heterotrimer, which proved a new mechanism of ligand 
bias.  
Ligand bias is a synonym for the ability of a ligand to differentially activate signaling 
pathways mediated via a single GPCR, which is due to different receptor 
conformational states induced by the ligand (Vauquelin and Van Liefde, 2005, Urban et 
al., 2007, Kenakin, 2009). Other terms found to describe this phenomenon, are 
“stimulus trafficking”, “functional selectivity”, “agonist-directed trafficking” or 
“ligand-induced selective signaling (LiSS)”. About 15 years ago, the phenomenon of 
ligand bias was described for the first time. Until then, a receptor was regarded to 
remain either in an inactive or an active state, and in an active state, induced by agonist 
binding, the receptor would be able to activate any signaling pathways linked to. Thus, 
data indicating ligand bias were not compatible with the prevalent pharmacological 
concepts and were first considered as artefacts resulting from e.g. interactions with 
unknown receptors, until more and more data emerged pointing at the phenomenon of 
ligand bias. In conclusion, the two-state receptor conformation model and the concept 
of “intrinsic efficacy” had to be revised and adapted to a multi-state receptor 
conformation model.  
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Ligand bias has been reported for several receptors, e. g. the β2-adrenoceptor (β2-AR) 
(Woo et al., 2009), the prostaglandin EP4 receptor (Leduc et al., 2009), the serotonin 
receptors 5-HT2A, 5-HT2B, 5-HT2C-VSV (Cussac et al., 2008), or the sphingosine-1-
phosphate receptor subtype 3 (SIP(3)) (Jongsma et al., 2009). Although in literature 
several reports on ligand biased agonism exist, until now only three cases of ligand 
biased antagonism have been reported (Mathiesen et al., 2005; Maillet et al., 2007; 
Dowal et al., 2011). Whereas Mathiesen et al. described biased antagonism of a ligand 
at the CRTH2 receptor conferring selective inhibition of receptor-β-arrestin recruitment 
without affecting receptor-G protein activation at the same time, Maillet et al. and 
Dowal et al. reported biased antagonism for the multi-G protein coupled receptors NK2 
and PAR1, respectively, based on selective inhibition of a single G protein pathway 
while not affecting another G protein pathway. In each of the three studies, the biased 
antagonism was determined to be induced by antagonists displaying allosteric features. 
Strikingly, the PAR1 receptor antagonist (Maillet et al., 2007) was even found to bind 
intracellular to helix 8 of the PAR1 receptor, as determined by point mutation studies. 
It is likely, that Gü 1654 might also induce its biased antagonism through allosteric 
binding to the OXE-R, hereby stabilizing a receptor conformation that preserves 
activation of Gαi-mediated downstream events, but at the same time completely 
precludes propagation of the Gβγ-mediated signal. In order to evaluate in the future if 
Gü 1654 might confer its unprecedented mechanism of ligand bias through an allosteric 
OXE-R binding site, extracellular or even intracellular, mutagenesis studies would have 
to be performed. Hereby, mutations analogous to those made by Dowal et al. should be 
considered for generation of OXE-R mutants. An intracellular located allosteric binding 
site has also been reported for antagonists at the CXCR2 receptor, and domain 
switching and point mutation studies determined that sensitivity towards the tested 
CXCR2 antagonists is conferred through the receptor´s C-terminus, as well as through 
Lys
320
 at the N terminus of helix 8 of CXCR2 (Nicholls et al., 2008; Salchow et al., 
2010). Thus, these findings could also provide supporting information regarding 
mutagenesis studies at the OXE-R.  
 
In BRET studies by Gales et al. (2006), BRET between receptor and Gβγ was analysed 
and determined to be an indicator of conformational changes propagated from an 
activated receptor to the G protein. In order to gain additional mechanistic insights into 
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the mode of biased antagonism of Gü 1654 and to assess, whether Gü 1654 affects 
proximity between the OXE-R and Gβγ, BRET assays were performed using the same 
BRET biosensors as Gales et al. These experiments were carried out by Lucas Peters 
from the group of Prof. Evi Kostenis.  
BRET was measured between the OXE-R tagged at its C-terminus with the energy 
donor Renilla luciferase (RLuc) and the Gγ2 subunit N-terminally fused to the energy 
acceptor GFP10. Upon stimulation with OXE, robust engagement of Gβγ was observed, 
which indicated a conformational change between the OXE-R and the Gβγ complex in 
which energy donor and energy acceptor move closer together (fig. 43a). This BRET 
response was significantly diminished in the presence of increasing concentrations of 
Gü 1654 (fig. 43a), suggesting that Gü 1654 prevents - at least in part - communication 
between the ligand-activated OXE-R and the Gβγ subunit by altering their proximity or 
relative orientation, respectively.  
 
Figure 43: Effects of Gü 1654 on OXE mediated BRET in the presence of Gü 1654. (a) 
OXE-induced BRET between the OXE-R fused to Renilla luciferase (OXE-R-Rluc) and 
GFP10-labelled Gγ (GFP10-Gγ) was concentration dependently attenuated at increasing 
concentrations of Gü 1654, as measured in HEK293 cells transiently expressing OXE-R-Rluc, 
GFP10-Gγ and Gβ. (b) The decrease of BRET between Gαi fused to Renilla luciferase (Gαi-91-
RLuc) and GFP10 labelled Gγ (GFP10-Gγ2) due to OXE-triggered opening of the nucleotide 
binding pocket of Gαi was not reversed by increasing concentrations of Gü 1654, as measured in 
HEK293 cells transiently transfected with the OXE-R, Gαi-91-RLuc, GFP10-Gγ2 and Gβ. 
Shown are mean values  SEM of 5-7 independent experiments each performed in 
quadruplicate. *** and *, significant effect to OXE; ns, non-significant effect to OXE. *, p < 
0.01 and ***, p < 0.001 according to one-way ANOVA with Bonferroni’s multiple comparison 
test. Data were kindly provided by Lucas Peters. 
 
A control using the HM74A fused to Renilla luciferase proved, that only BRET 
interaction between the OXE-R and Gβγ was specifically inhibited by Gü 1654 (data 
not shown). Finally, Gü1654 was completely ineffective when tested for its ability to 
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inhibit opening of the Gαi nucleotide binding pocket (Fig. 43b) as determined in BRET 
assays where a OXE triggered decrease of BRET between Gαi and Gβγ using the 
appropriate sensors of Gαi and the Gβγ complex (Gαi-91-RLuc, GFP10-Gγ2; Gales et 
al., 2006) was detected.  
As these BRET data showed that contact between the OXE-R and Gβγ is only partially, 
and not completely diminished in the presence of the highest concentration of Gü 1654, 
it appeared intriguing that only partially attenuated contact between OXE-R and Gβγ is 
competent to completely silence downstream signaling of Gβγ. But, however, from a 
different point of view, “only” partial inhibition of receptor-Gβγ contact in the presence 
of Gü 1654 truly reflects the biased antagonism of Gü 1654 on Gi protein subunit 
signaling, as probably Gαi activation is only provided due to partially and not 
completely diminished OXE-R-Gβγ contact.  
Models of receptor-mediated G-protein activation presume that Gβγ plays a crucial role 
in receptor-G protein interaction and G protein activation, and that Gβγ actively 
participates in receptor-G protein activation (Bourne, 1997; Ford et al., 1998; Iiri et al., 
1998). Due to the “lever-arm” (Lichtarge et al., 1996; Rondard et al., 2001) and the 
“gear-shift” model (Cherfils and Chabre, 2003), Gβγ is involved in mediation of GDP 
release from the Gαi nucleotide binding pocket, whereas the “C-terminal latch” model 
(Herrmann et al., 2004; Gautam, 2003; Kisselec and Downs, 2003) presumes the C-
terminus of Gγ to present a receptor contact site before GDP release is enabled. These 
models imply, that, if the initial contact between agonist stimulated receptor and Gβγ is 
prevented, – e.g. due to a receptor conformation change induced by an antagonist – G 
protein activation cannot be initiated.  
Indeed, BRET experiments performed by Gales et al. (2006) monitoring interactions 
between the α2A-adrenoceptor fused to Renilla luciferase and GFP10 labelled Gβ or 
GFP10 labelled Gγ, respectively, proved that agonist-induced BRET between the α2A-
adrenoceptor and the Gβγ dimer was completely abrogated after pre-treatment with the 
selective α2A-adrenoceptor antagonist RX 821002 (Newman-Tancredi et al., 1998). In 
the same work, agonist stimulated decrease of BRET between Gαi and Gγ was also 
reversed after antagonist pre-treatment indicating the need of receptor-Gβγ interaction 
for Gα activation.   
In further experiments, the conformational changes within the G protein heterotrimer 
induced during receptor-mediated G protein activation were analysed. The results 
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concerning the structural model of G protein activation were found to be compatible 
with the “gear-shift” model (Cherfils and Chabre 2003). 
Thus, OXE-R BRET assays imply - beneath the finding that obviously partially 
attenuated contact between OXE-R and Gβγ is competent to completely silence 
downstream signaling of Gβγ -, that (i) OXE-R-mediated G protein activation is 
conferred through OXE-R-Gβγ contact, and that (ii) although OXE-R-Gβγ contact is 
partially diminished in the presence of Gü 1654, the remaining contact between the 
OXE-R and the Gβγ dimer is still sufficient for activation of Gαi. 
 
In conclusion, the identification of the first GPCR antagonist able to discriminate 
between receptor signaling on the level of an individual Gαβγ heterotrimer can be 
reported. This unprecedented mechanism of ligand bias suggests an ever increasing 
number of relevant conformational states that may be adopted by GPCRs and may link 
them to defined signaling routes. Hence, this new mechanism of ligand bias will state a 
new paradigm for pathway specific drug design in order to gain allosteric modulators 
with improved therapeutic window and increased selectivity, and, in addition, offers 
new implications on the strategy of drug screening, as appropriate assays suited to 
detect signaling via the Gβγ pathway will need to be established.   
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The lipid mediator 5-oxo-ETE is a metabolite of the 5-lipoxygenase pathway and acts as 
a potent chemoattractant on eosinophils and neutrophils. OXE-induced effects are 
mediated via the Gi coupled 5-oxo-ETE receptor OXE-R, which is mainly expressed on 
immune cells like eosinophils, neutrophils, basophils and monocytes. The OXE-R is 
implicated to play a pivotal role in inflammation and inflammatory diseases. For 
analysis of pathophysiologic effects of OXE-R signaling, an OXE-R antagonist would 
be needed, but to date, no small molecule OXE-R antagonist has been reported.  
In the present thesis, a biomolecular screening in combination with a virtual screening 
was performed to discover OXE-R antagonists. In calcium mobilization assays, using a 
human recombinant cell line overexpressing the OXE-R and the promiscuous Gα 
subunit G16, three compounds were identified with inhibitory effects on the OXE-R G16 
pathway: Gü 1157, Gü 1158 and Gü 1654. To explore the antagonistic efficacy of the 
compounds on the various signaling pathways of the OXE-R, a number of functional 
assays had to be established allowing to monitor G protein-dependent and G protein-
independent effector activation of the OXE-R using recombinant cells overexpressing 
the OXE-R. In cAMP accumulation assays Gü 1157, Gü 1158 and Gü 1654 were 
analyzed on the native Gi signaling pathway of the OXE-R. Surprisingly, the 
compounds did not show inhibitory activity on the Gi signaling pathway of the OXE-R, 
so that Gü 1157, Gü 1158 and Gü 1654 were assumed to exhibit a biased antagonism at 
OXE-R G16 and Gi signaling.To confirm this hypothesis, DMR assays were established 
and Gü 1157, Gü 1158 and Gü 1654 were analyzed on the discrete OXE-R G16 and Gi 
pathways, respectively. The biased antagonism was confirmed for Gü 1654, but not for 
Gü 1157 and Gü 1158, which failed to inhibit OXE-R G16 DMR responses and were not 
pursued further.  
The OXE-R was analyzed for β-Arrestin recruitment capabilities using BRET assays, 
and OXE-R β-Arrestin recruitment was uncovered to occur also in the absence of Gi 
protein activation, which provides evidence for a hitherto unknown G protein-
independent signaling pathway of the OXE-R. Analysis of Gü 1654 on OXE-R β-
Arrestin translocation revealed inhibitory effects on OXE-mediated β-Arrestin 
recruitment in the presence and absence of activated Gi proteins, indicating that Gü 
1654 is a potent OXE-R antagonist also on a non-Gi-mediated signaling pathway.  
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It was evaluated if Gü 1654 maintains its biased antagonism on endogenously expressed 
OXE-R in human primary cells. Intriguingly, analysis of Gü 1654 on OXE-R Gi 
signaling in eosinophils and neutrophils by using two different assays monitoring Gi-
mediated cellular effects uncovered Gü 1654 to inhibit OXE-R Gβγ mediated calcium 
flux assays but not to inhibit OXE-R Gαi signaling in cAMP assays.  
In the present thesis, Gü 1654 was discovered as a novel small molecule OXE-R 
antagonist which is competent to selectively inhibit OXE-R signaling via different 
subunits of the same heterotrimeric Gi protein, implying a new mechanism of ligand 
bias. 
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AC adenylyl cyclase 
ADP adenosine 5’-diphosphate 
ATP adenosine 5’-triphosphate 
bp base pairs 
BRET bioluminescence resonance energy transfer 
cAMP cyclic adenosine monophosphate 
cDNA complementary DNA 
DAG diacylglycerol 
H2O water 
DMR dynamic mass redistribution 
DNA deoxyribonucleic acid 
DRC dose-response curve 
EC50 concentration of half maximum effect 
ERK extracellular-signal regulated kinase 
FSK forskolin 
g gram, acceleration by gravity 
GDP guanosine 5′-diphosphate 
GFP green fluorescent protein 
GPCR G protein coupled receptor 
G protein guanine nucleotide-binding protein 
GRK G protein coupled receptor kinases 
GTP guanosine 5′-triphosphate 
h Human, hour 
HTRF homogeneous time resolved fluorescence 
IP1 inositol 4-phosphate 
IP3 inositol 1,3,4-triphosphate 
JNK c-Jun N-terminal kinase 
kb kilo base(s) 
log M logarithm of molar concentration to base 10 
M molar concentration (mol/liter) 
MAPK mitogen-activated protein kinase 
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mBRET milliBRET  
min minute(s) 
ml milliliter
 
µl microliter 
µM micromolar 
n number 
nm nanometer 
nM nanomolar 
ns non-significant 
OD optical density 
PAR protease-activated receptor 
pEC50 negative logarithm of EC50 
PI phosphatidylinositol 
PI3K phosphatidylinositol 3-kinase 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
pm picometer 
PTX Pertussis toxin 
RhoA Ras homolog gene family, member A 
RLuc Renilla luciferase 
rpm rounds per minute 
RT room temperature 
RWG resonant waveguide grating 
s second(s) 
SEM standard error of mean 
TM transmembrane 
TR-FRET time-resolved fluorescence resonance energy transfer 
U unit 
UV ultraviolet 
V volt 
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Appendix 
Chemical structures of compounds tested in HEK-OXE-R-G16 calcium mobilization 
assays (section 3.1.2, 3.1.4, 3.1.5). 
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